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Introduction 
Hepatitis B virus 
In 1965 Blumberg et al. published their classic paper in which the discovery 
of australia antigen was described (1). In 1968 the australia antigen was identified 
as hepatitis B virus surface antigen, causing serum hepatitis (2,3). For his break-
through in hepatitis B research, Blumberg was awarded in 1976 with the Nobel 
Prize in physiology and medicine. 
The hepatitis B virus is a double-stranded DNA virus, belonging to the 
group of hepadna viridae ( 4,5). 
Hepatitis B Virus 
HBcAg 
HBsAg 
DNA-P 
ds-DNA 
HBeAg 
Figure 1. Model of the hepatitis B virus: DNA-P: DNA polymerase; ds-DNA: double-stranded DNA; 
HBsAg: hepatitis B suiface antigen; HBcAg: hepatitis B core antigen; HBeAg: hepatitis B e~antigen. 
Hepatitis B vaccine 
Active immunization against hepatitis B was first introduced in 1970 by 
Krugman et al (6). A vaccine was prepared in which boiled diluted plasma from an 
Australia antigen carrier stimulated antibody in human subjects and protected 
against hepatitis B infection. This paved the way for manufacturing hepatitis B 
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vaccine. From pooled plasma of asymptomatic, healthy, high titre HBsAg carriers, 
HBsAg particles were derived for the preparation of plasma-derived hepatitis B 
vaccine. Inactivations steps insured non-infectivity and adjuvants were added as a 
preservative. The limited supply of suitable plasma of HBV carriers and the time-
and money- consuming procedures involved to assure safety and purity led to the 
development of recombinant hepatitis B vaccines. The vaccine is prepared from 
hepatitis B surface antigen produced in recombinant baker's yeast (Saccharomyces 
cerevisiae) (7). Adverse reactions are minimal and consist of transient pain and 
swelling at the site of injection in 10-15% of vaccinees. Another 1-3% of recipients 
suffer from low-grade fever and malaise after administration of hepatitis B vaccine. 
History of perinatal hepatitis B vaccination 
Hepatitis B virus (HBV) infection and its sequelae, cirrhosis and hepatocel-
lular carcinoma, has been a vaccine-preventable disease for a decade. Hepatitis B is 
still a major public health problem: over half of the world population has been 
infected with HBV, 350.000.000 people are chronically infected HBV carriers, who 
constitute the reservoir of infection. Forty percent of persisitently infected people 
will die of the consequences of the disease (8). The carrier rate of HBsAg varies 
world-wide from less than 1% in countries as Britain, Scandinavia, US and the 
Netherlands to more than 3% in Greece and Italy and up to 10-15% in Africa and 
the Far East (9). Perinatal infection of newborns with HBV from HBsAg carrier 
mothers is one of the main causes of HBV infections and of maintenance of the 
HBV reservoir (10-12). In 1982, a study was initiated in the Netherlands in which 
it was determined that in three test areas, pregnant women could be identified as 
HBsAg carriers by screening and that combined passive-active immunization of 
newborns of HBsAg carrier mothers could be carried out, leading to active 
development of sufficient anti-HBs in over 90% of cases (13,14). Results of 24-
months follow up were described in the dissertation of Maze]: "Prevention of 
perinatal hepatitis B in neonates in the Netherlands" (15). These outcomes were in 
agreement with several other studies in the early 1980's, which showed that 
passive-active immunization of newborns of HBsAg positive mothers was safe, 
effective and immunogenic in 80-100% of cases (16-19). On the basis of the results 
of these studies, the health authorities in the Netherlands decided, in 1989, to 
introduce a national program to test all pregnant women for HBsAg and to 
administer passive-active hepatitis B immunization to newborns of HBsAg positive 
mothers (20). It was estimated that, with a mean birth rate of 170.000, this program 
could prevent 400 HBV infected neonates (probably leading to 15 acute hepatitis 
B, 1 fulminant hepatitis B, 250 HBV carriers) yearly in the Netherlands (15). Since 
the human hepatitis B virus has no known animal reservoir, a systemic vaccination 
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program against hepatitis B, including vaccination of all newborns and young 
children could theoretically lead to the eradication of hepatitis B. The WHO 
Expanded Program on Immunization has called for all countries with an HBV 
carrier prevalence of 8% or greater to have universal vaccination integrated into 
their routine immunization programs by 1995, and for all other countries by 1997 
(21). Adapted guidelines are therefore needed in the Netherlands, with a estimated 
HBV carrier prevalence of 0.8% (14), for the introduction of national hepatitis B 
immunoprophylaxis for all newborns. 
HBsAg Prevalence 
II >8%-High 
ffiill] 2-7%- Intermediate 
D <2%-Low • Program underway 
CDC 
Figure 2. Hepatitis B vaccine policy of infant immunization in 1993. (from M. Kane, World Health Or-
ganization, Geneva, Switserland; with permission). 
Failure of hepatitis B immunization in infants 
Inadequate responses to hepatitis B vaccine occur in 2-4% of properly 
vaccinated infants of HBsAg-positive carrier mothers: 1-2% become HBsAg 
positive and another 1-2% are not able to develop sufficient amounts of anti-HBs 
for longlasting immunity against HBV. An anti-HBs antibody level of more than 10 
!U/L is considered to provide protection against hepatitis B infection (22), anti-
HBs of more than 100 IU/L for long-lasting immunity (23). Failure of neonatal 
immunoprophylaxis could be due to either in utero infection (17), a high dose of 
HBV, transmitted during delivery and related to maternal high-level viraemia 
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(24,25), insufficient neutralization capacity of the HB!g injection or failure to 
respond adequately to the vaccine, given in an adequate dose, due to genetic (26) 
or acquired causes (27-29). The question remained if preterm infants have adequate 
responses to hepatitis B immunization in comparison with full term infants. 
Aims of the thesis: 
1. To assess efficacy, immunogenicity and safety of different hepatitis B 
immunization schedules (dose, number of doses and time of onset vacci-
nation) in neonates of HBsAg positive mothers (chapter 2 and 5) and in neo-
nates of HBsAg negative mothers (chapter 3 and 4 ). 
2. To assess hepatitis B vaccination in infants, with a gestational age of less 
than 37 weeks (chapter 6). 
3. To investigate additional hepatitis B vaccination in non-infected neonates, 
with inadequate response after primary vaccination (chapter 7). 
4. To evaluate causes of failure of neonatal hepatitis B vaccination (chapter 8 
and 9). 
5. To evaluate the follow-up of infants who became infected with hepatitis B 
in spite of passive-active hepatitis B immunization (chapter 10). 
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Chapter 2 
Passive active immunization of infants of hepatitis 
B e antigen-positive mothers: comparison of the 
efficacy of early and delayed active immunization 
Grosheide PM, Canho del R, Heijtink RA, Nuijten ASM, Zwijnenberg J, Banffer 
JRJ, Wladimiroff YW, Botman MJ, Maze! JA, de Gast GC, Christiaens GCML, 
Gerards U, Fetter WPF, Baerts Wand Schalm SW 
American Journal of Diseases in Children: in press 
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Abstract 
Objective: To assess the efficacy of late active immunization against hepatitis B 
concomitant with diphtheria, pertussis, tetanus and polio vaccine in high-
risk infants receiving hepatitis B immune globulin at birth. 
Design: Randomized study of infants born to mothers positive for hepatitis B 
surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). 
Setting: Three large city hospitals and one rural area providing prenatal care and 
obstetric services. 
Subjects: Eighty neonates of HBsAg- and HBeAg-positive carrier mothers 
received 0.5 ml!kg of body weight hepatitis B immune globulin within two 
hours of birth and hepatitis B vaccine (10 ~g) at 0, 1, 2 and 11 months of 
age (group A) or at 3, 4, 5 and 11 months of age concomitant with diph-
theria, pertussis, tetanus and polio immunization (group B). A second dose 
of hepatitis B immune globulin was given to infants on schedule B at 3 
months. 
Main outcome measures: Blood samples were collected at 0, 3, 6, 11, and 12 
months of age and tested for antibodies to hepatitis B core antigen (anti-
HBc) and HBsAg. Follow-up visits were scheduled annually up to 5 years 
of age. 
Results: Eight infants were excluded from analysis. During the study period six 
children became HBsAg carriers, three in each group, which corresponds to 
a five-year incidence of infection of 9% and 8% for groups A (three of 35) 
and B (three of 37), respectively. Subclinical infections (persistent anti-HBc 
positivity beyond month 12 or appearance of anti-HBc) were encountered in 
another eight infants (four in each group). 
Conclusion: Late active immunization starting at 3 months of age appears to 
provide similar protective efficacy as active immunization starting at birth 
when combined with hepatitis B immune globulin at 0 and 3 months of age. 
16 
Introduction 
The current goal of immunoprophylaxis for newborns of mothers positive 
for hepatitis B surface antigen (HBsAg) is prevention of the chronic hepatitis B 
carrier state. 
In June 1982 plasma-derived hepatitis B vaccine was licensed in the 
Netherlands and in July 1982 a program was initiated to determine a practical and 
effective immunization schedule for the prevention of hepatitis B in neonates of 
HBsAg-positive mothers. Because more than 95% of the relevant population parti-
cipates in the national immunization program in the Netherlands, incorporation of 
hepatitis B vaccine into the diphtheria, pertussis, tetanus and polio (DPTP) 
vaccination program is presumed to yield the highest compliance and the lowest 
costs. Therefore we investigated two schedules of passive-active immunization to 
find out whether the simultaneous injection of hepatitis B vaccine and DPTP 
vaccine (delayed active immunization) provided the same protection against 
perinatal infections from HBsAg- and hepatitis B e antigen (HBeAg)-positive 
carrier mothers as early active immunization starting directly after birth. 
Preliminary results of this study were reported earlier (1-2). Then, 34 infants 
of HBsAg- and HBeAg-positive mothers had entered the study. The final results on 
the protective efficacy of passive-active immunization in 80 high-risk infants after 
a follow-up of five years are reported herein. 
Methods 
Participating centers 
The study was performed in four centers in the Netherlands: three large city 
hospitals in Utrecht (n=1) and Rotterdam (n=2) and the rural area Twente Gelderse 
Achterhoek where the number of home deliveries is high. 
Ethics 
Early in 1982 permission for the study was obtained from the local Medical 
Ethics Committees. 
Hepatitis B screening 
In July 1982 HBsAg screening of pregnant women was started in the four 
centers. Blood samples obtained from all pregnant women during their first visit to 
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the prenatal clinic of the participating centers were tested for the presence of 
HBsAg. Pregnant women with a positive test during the initial visit underwent a 
repeat test for HBsAg at week 2S of pregnancy. A woman was considered a 
HBsAg-positive carrier if the repeat test was positive for HBsAg. At the prenatal 
visit following the diagnosis of HBsAg carriership, the mother was informed about 
the immunization study program. Informed consent was obtained from the mother 
and information on country of birth and parity was noted in the woman's file (base-
line characteristics). Randomization for either early or delayed active immuniza-
tion took place at the local center. 
At delivery an additional blood sample was obtained from the mother to verify 
the eligibility of her infant for the study. When a pregnant woman came to the two 
participating hospitals in Rotterdam for delivery and no HBsAg test result from 
prenatal visits was available, a rapid HBsAg test was performed. Results were avai-
lable the next day before hospital discharge of the mother. If the rapid HBsAg test was 
positive, the mother was asked for informed consent and her baby was randomized. 
All pregnant women who were positive for HBsAg were also tested for the 
presence of HBeAg. The enrollment of infants born to HBsAg- and HBeAg-
positive mothers closed December 31, 1987. 
Immunization schedules 
Infants received an intramuscular injection of 0.5 ml/kg of body weight of 
hepatitis B immune globulin (HBig) within 2 hours of birth except for infants of 
perinatally detected HBsAg carrier mothers who received HB!g as soon as 
possible. HB!g prepared by the Central Laboratory of the Netherlands Red Cross 
Blood Transfusion Service, Amsterdam, contained 100 to 150 international units of 
antibodies to the hepatitis B surface antigen (anti-HBs) per milliliter and was 
stored at 2°C to soc. The HB!g was given intramuscularly in the anterolateral 
region of the thigh by the individual assisting in the delivery. 
For active immunization, infants were referred to a paediatrician. Infants on 
schedule A received 0.5 ml (10 fAg) of plasma hepatitis B vaccine (HBvax) 
intramuscularly in the anterolateral thigh within two days of birth and 1, 2, and 11 
months later, whereas those on schedule B received an equal dose of vaccine at 3, 
4, 5, and 11 months of age. The vaccine (Merck Sharp & Dohme, West Point, Pa) 
contained 20 etg/ml of surface antigen and was stored at 2°C to soc. A second dose 
of HB!g (100 to 150 IU of anti-HBs/ml) was given at 3 months to infants receiving 
delayed active immunization according to schedule B. 
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Blood sampling 
Immediately after delivery, cord blood was obtained from all infants. 
Follow-up blood samples were obtained at 3, 6, 11, and 12 months of age and then 
annually for at least five years. 
Laboratory 
Serum samples obtained from mothers during the study in Utrecht and 
Rotterdam (the Netherlands) were assayed for HBsAg by radioimmunoassay 
(Ausria-II, Abbott Laboratories, Chicago, Ill). The reversed passive hemag-
glutination assay (Auscell, Abbott) was used for initial screening in the Twente 
Gelderse Achterhoek area and for rapid HBsAg testing in Rotterdam. All positive 
samples detected by the reversed passive hemagglutination assay were confirmed 
by radioimmunoassay. When a mother was HBsAg-positive, the HBeAg status was 
assessed (Abbott-HBe ). Serum samples from infants were assayed for anti-HBs by 
radioimmunoassay (Ausab, Abbott). The results were expressed in international 
units per liter (IU/1) with the aid of the World Health Organization reference serum. 
Samples obtained at birth and 12 months of age, as well as the annual samples, 
were also tested for antibodies to hepatitis B core antigen (Corab, Abbott). The 
presence of HBsAg was assayed in all samples with anti-HBs values below 100 
IU/1. 
Hepatitis B infections 
Among infants two types of hepatitis B infection were registered after 
birth. A hepatitis B virus (HBV) infection was considered to have occurred if an 
infant became positive for HBsAg (cord blood excluded) or anti-HBc without 
HBsAg was observed after month 12 (3-4). Anti-HBc positivity had to be present 
on two or more consecutive occasions to rule out false low-level anti-HBc 
reactivity. Anti-HBc positivity without HBsAg at month 12 was considered to be 
due to maternal transmission of anti-HBc. Anti-HBc IgM was not considered to be 
a representative marker of acute hepatitis B infection since infants of HBsAg 
carrier mothers lacked this marker when infected perinatally (5). An increase in 
the anti-HBs level alone was not considered an HBV infection. An infant who was 
HBsAg-positive for more than six months was considered to be an HBsAg carrier 
(3). Infants who had no HBsAg-positive serum samples but were anti-HBc 
positive after month 12 were considered to have had a subclinical infection with 
HBsAg. 
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Randomization 
From July 1, 1982 until December 31, 1987 all HBsAg-positive mothers 
admitted to the study were randomly assigned to one of two treatment groups. 
Randomization according to Peto et al occurred in each local center separately 
using numbered sealed opaque envelopes (6). Each block of six envelopes con-
tained three cards with treatment A and three cards with treatment B. 
Stratification according to prenatal and perinatal detection of HBsAg was applied 
in the hospitals in Rotterdam since strict adherence to immunization schedules 
could not be guaranteed for the infants of perinatally detected HBsAg-positive 
mothers. 
Statistics 
The number of infants born to HBeAg-positive HBsAg carrier mothers 
available during the enrollment period determined the sample size. 
The degree of similarity between the two treatment groups was demonstra-
ted by comparing baseline characteristics of the HBsAg- and HBeAg-positive 
mothers. The baseline characteristics were compared for all mothers who agreed to 
treatment of their infants (n=80) and for mothers whose infants received proper 
treatment according to schedule A orB (n=72). Differences in proportions related 
to country of birth of the mothers, parity, and rapid screening between treatment 
groups were compared using the Chi-square test and Fisher's exact test in the case 
of small numbers. Median ages of mothers were compared using the Wilcoxon test. 
Differences in number of HBV events between groups were calculated with the 
Fisher's exact test and 95% confidence intervals (CI). The exact values for 95% CI 
are given in Geigy Scientific Tables (7). 
Results 
A total number of 527 pregnant women was found to be repeatedly HBsAg-
positive by screening; 92 (17%) of these mothers were also HBeAg-positive. 
Eighty infants of HBsAg- and HBeAg-positive mothers were born in the study 
period and eligible for passive-active immunization (38 according to schedule A; 
42 according to schedule B). 
Eight infants (schedule A, three infants; schedule B, five infants) were 
excluded from further analysis: three infants never received vaccine (schedule A, 
one infant; schedule B, two infants), three infants received two doses of vaccine 
but no serum sample was available after month 0 (schedule A, two infants; 
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Table 1. Baseline characteristics of HBsAg- and IIBeAg-positive mothers of infants immunized according 
to schedule A or B. 
Mothers Schedule A Schedule B P-value 
n = 35 n = 37 
Median age, years 23 (19;33)* 24 (17;38) P=0.06t 
Country of birth, No (%) P=0.92o 
Netherlands + other 3 (8.6%) 2 (5.4%) 
Mediterranean 15 (42.9%) 16 (43.2%) 
Surinam 5 (14.3%) 7 (18.9%) 
Asia 12 (34.3%) 12 (32.4%) 
§ 
Rapid screening, No (%) 2 (5.7%) 2 (5.4%) P= 1.00 
Primigravidae, No (%) 16 (45.7%) 10 (27.0) P=0.10° 
* Numbers in parentheses indicate fifth to 95th percentile. 
t Wilcoxon test. 
° Chi-square test. 
§ Fisher's exact test. 
Table 2. Time at which infants who became HBsAg carriers despite passive-active immunization were first 
positive for /JBsAg. 
HBsAg-positive anti-HBs in lUll 
case sche- ot 3 6 11 12 months ot 3 6 11 12 
dule 
----
1 A + + + + 0 16 2 0 0 
2 A + + + 0 45 39 0 0 
3 A + + + + + 0 0 0 0 0 
4 B + + + + + 0 0 0 0 0 
5 B + + + + 0 29 0 0 6 
6 B + + 0 38 17 0 0 
Plus sign(+) indicates HBsAg-positive and minus sign(-) indicates HBsAg-negative. 
t Cord blood. 
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schedule B, one infant), and one infant died of congenital abnormalities 10 days 
after birth (schedule B, one infant). One infant received the wrong immunization 
schedule (schedule B, one infant), but the last available blood sample tested was 
negative for HBsAg. 
In Table 1 baseline characteristics are presented for the 72 mothers whose 
infants received proper treatment. The baseline characteristics of these 72 mothers 
did not differ from those for the total group of 80 mothers originally randomized. 
HBsAg positivity was found in three (9%) of 35 infants in group A (Cl, 1.8 
to 23.1) and three (8%) of 37 infants in group B (CI, 1.7 to 21.9). All HBsAg-
positive infants became carriers. The onset of HBsAg positivity in those infants 
who could not be protected occurred within the first 11 months of life (Table 2). 
Two infants were already HBsAg-positive in cord blood and thereafter. The other 
four carrier infants were first HBsAg-positive at 6 or 11 months of age; their anti-
HBs antibody levels varied from 16 IU/1 to 45 IU/1 at month 3 and were absent 
from month 6 onwards in all but one case. Infant 5 had concurrent HBsAg and 
anti-HBs at month 12. 
Four (13%) of 32 infants in group A (CI, 3.5 to 29.0) and four (12%) of 34 
infants in group B (CI, 3.3 to 27.5) exhibited anti-HBc beyond month 12 on at least 
two consecutive occasions; in all cases the development of anti-HBs was normal 
during the first 12 months of age (Table 3). Four infants (patients 1 through 4), two 
in each group, were anti-HBc positive from month 12 onwards. The other four 
infants became anti-HBc positive after month 12. Anti-HBs titers varied consi-
derably in these anti-HBc-positive infants and either increased or (slowly) decrea-
sed. HBsAg was never observed in these infants. 
The frequency of HBV events per group, seven (20%) of 35 infants in group 
A (CI, 8.4 to 36.9) and seven (19%) of 37 infants in group B (CI, 8.0 to 35.2), was 
not statistically different. The 95% CI for the difference between the two popu-
lation proportions ranges from -17% to 19%. 
The HBsAg- and HBeAg-positive mothers who infected their infants were 
all detected during pregnancy; they had a normal pregnancy and spontaneous 
delivery. The six infants who became HBsAg carriers received HB!g directly after 
birth and, except for patient 5 who received the second vaccination 3 weeks late, 
all infants were immunized according to schedule. 
To determine whether mothers from Asia with suspected high levels of the 
virus (8,9) were more likely to infect their offspring, we evaluated the ethnic 
distribution of the HBsAg- and HBeAg-positive carrier mothers in relation to the 
perinatal transmission of HBV. The ethnic distribution of mothers with HBV 
infected infants was similar in groups A and B (Table 4 ). When HBV infected 
infants from the two groups were combined and analyzed according to maternal 
origin, differences became apparent. In contrast to our expectations, the rate of 
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Table 3. Appearance/persistence of anti-1-!Bc and anti-HBs in follow-up sera from infants with subclinical 
infection despite passive-active immunization according to schedule A and B. 
anti-HBc at month anti-HBs in IU/L at month 
case sche- 12 24 36 48 60 12 24 36 48 60 
dule 
1 A + + + + NT 1299 2371 7643 4080 NT 
2 A + + NT NT + 1183 134 90 NT 34 
3 B + + + + + 559 3903 2962 1185 1037 
4 B + + + + + 25660 21555 10195 10989 NT 
5 A + + + 2280 332 309 301 144 
6 A + + + + 4989 349 209 175 182 
7 B NT + + 2191 725 NT 1043 795 
8 B + + NT 898 78 110 32 NT 
NT indicates no test result available 
Plus sign(+) indicates anti-HBc positive 
Minus sign(-) indicates anti-HBc negative. 
Table 4. I-lBV infections (I-lBsAg carriers and anti-HBc positivity after month 12) by study group and 
ethnic distribution. 
Number of infants NumberofHBV infections 
Schedule Schedule 
Country of birth A B Total A B Total 
Mediterranean 15 16 31 5 (2) 6 (3) 11 (5) 
Asia 12 12 24 2 (1) 1 (-) 3 (1) 
Total 27 28 55 7 (3) 7 (3) 14 (6) 
Number in parentheses indicate number of l-IB sAg carrier infants 
23 
transmission of HBV for mothers of Asian origin (three [13%] of 24) tended to be 
lower (CI, 2.7 to 32.4) than that for mothers of Mediterranean origin (11 [36%] of 
31; CI, 19.2 to 54.6). This trend in frequency of HBV infections was just above 
statistical significance (P=0.05; Chi-square test). 
Discussion 
This study demonstrates that the frequency of hepatitis B antigenemia for 
infants of HBsAg- and HBeAg-positive mothers after delayed active immu-
nization, starting at 3 months, is similar to that obtained with early active immu-
nization starting directly after birth: 8% and 9%, respectively. Only six (8%) of 72 
infants (CI, 3.1 to 17.3) became HBsAg carriers, a rate comparable with that found 
in other passive-active immunization studies with either plasma vaccine or 
recombinant vaccine (8, 10-14 ). Our results are in agreement with the findings of 
Beasley et al. who demonstrated HBsAg carrier rates of 2% for the delayed 
vaccination also starting at 3 months vs 6% for the early vaccination given 4 to 7 
days after birth (10). 
Since the number of HBsAg-positive infants in both studies was relatively 
small and anti-HBc is the most sensitive marker of HBV infection, we also 
compared the number of anti-HBc positive infants without HBsAg in the two 
groups. Anti-HBc positivity was found for eight infants, four in each group. All 
subclinical infections were observed in infants with an active immune response to 
vaccine; none of these infants had development of the carrier state or became 
HBsAg-positive. This indicates that infants with an adequate initial anti-HBs 
response remained protected against HBV carrier state for at least five years. After 
the follow-up period of five years, the total number of hepatitis B infections was 
similar for both groups; seven (20%) in group A and seven (19%) in group B. The 
95% CI for the difference between the two groups ranges from -17% to 19%, 
showing the imprecision due to the limited sample size. Further studies with larger 
numbers of neonates will be needed to confirm these results, although the low 
number of HBV infections suggests no major clinical relevance. 
It is unlikely that the HBV infections were generated by vaccine-induced 
escape mutants (seen in Mediterranean countries) since these mutants are characte-
rized by HBsAg and concomitant adequate levels of nonneutralizing anti-HBs (15). 
In the Netherlands, where prenatal screening of pregnant women is current 
policy, immunoprophylaxis with vaccine alone is not considered and HB!g is 
always given at birth. The cardinal question then becomes what vaccination 
schedule is feasible with high compliance and what schedule is most effective? We 
tested one schedule we thought would be the most effective (0, 1, 2 and 11 months) 
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and one schedule we thought would be associated with highest compliance (3, 4, 5, 
and 11 months). The results showed no difference in efficacy, confirming the 
original observations by Beasley et al. (10), and higher immunogenicity (2). In this 
setting, the compliance with both schedules was similar but early active 
immunization does not correspond to the routinely scheduled immunization visits 
in practice. 
In many countries, hepatitis B immunization starting immediately after birth 
is advocated. Although this approach is scientifically well founded, both the 
compliance related to multiple injections and the costs related to additional 
physician visits might interfere with high compliance to the vaccination programs. 
In our opinion, both our study and the study of Beasley et al. demonstrate that the 
timing of the start of active immunization within the period of 0 to 3 months after 
birth is of minor importance for neonates receiving HB!g directly after birth (10). 
This conclusion is of considerable importance when designing strategies for HBV 
immunization programs with a high degree of compliance. Current experience 
suggests that high compliance is difficult to achieve with many injections on 
separate months (16-17). In Italy, where mass vaccination against hepatitis B was 
recently introduced, the highest compliance rate was observed in the babies who 
received hepatitis B vaccination at the same time as the mandatory childhood 
vaccinations (98% ), whereas it was 80% in babies who received the vaccines 
separately (16). 
An extra dose of vaccine at month 0 with no proven benefit would mean 
additional effort and cost. Conversely, data on the immunogenicity and efficacy of 
a vaccination schedule starting at birth with a second dose at month 3 are 
unavailable. Increasing the interval between the first and the second dose of 
vaccine beyond the recommended interval of four weeks has been reported to 
decrease the antibody response (18). 
If the hepatitis B vaccine could be given at the same time as DPT or DPT-
polio immunization, the number of physician visits could be reduced: in addition, 
the number of injections could be reduced if hepatitis B vaccine could be 
incorporated into the DPT vaccine. 
Furthermore, the influence of the vaccination schedule is demonstrated by 
significantly higher anti-HBs response in infants receiving late active immuni-
zation (1-2). Age at the first injection of vaccine is a matter of controversy because, 
on the one hand it is important to protect the neonates as early as possible, delivery 
being the most crucial time to get HBV infection: on the other hand, the 
physiological immunosuppression of newborns may produce a less effective 
response to vaccination. 
A potential drawback of delayed active immunization may be the need for an 
additional HBig injection, as was given to infants in our study as well as in the study 
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of Beasley et al. (10). The need for a second dose of HBig with delayed vaccination, 
however, has not been established. In fact, an efficacy study showed no evidence of 
enhanced protection when an additional dose of HB!g is used (Grosheide et al.: 
submitted for publication). It seems reasonable to expect that active immunity will 
develop rapidly enough to eliminate the need for subsequent doses of HBig (19). 
In the Netherlands, a low prevalence area with a high percentage of home 
deliveries, vaccination starting directly after birth does not fit easily into the child 
care program; OPT-polio injections are given at the ages of 3, 4, 5 and 11 months. 
Passive immunization of infants of HBsAg-positive mothers immediately after 
birth by the midwife or obstetrician, followed by active immunization by the physi-
cian responsible for routine infant immunization, appears feasible. Because com-
pliance to OPT-polio vaccination in the Netherlands reaches 95%, simultaneous 
administration of the hepatitis B vaccine with OPT-polio vaccination is likely to be 
associated with a similar high compliance for hepatitis B. Evaluation of infant 
immunization would occur within the existing health care system. At virtually no 
cost and without extra effort, infants can be immunized against hepatitis B. The 
results of this study open the way for general application of hepatitis B vaccine, 
incorporated into a OPT vaccine, in countries that provide hepatitis B immune glo-
bulin prophylaxis at birth to high-risk neonates. 
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Abstract 
The immunogenicity of a full dose of recombinant DNA yeast-derived 
hepatitis B vaccine (Engerix-B) was assessed in healthy neonates in order to 
compare three candidate vaccination schemes. After randomization 162 newborns 
of HBsAg-negative mothers entered the study. Neonates received hepatitis B 
vaccine according to a four-dose vaccination scheme starting either at month 3 
(scheme I; months 3, 4, 5 and 11) or at birth (scheme III; months 0, 1, 2 and 11). 
Another group of neonates received hepatitis B vaccine according to a three-dose 
scheme starting at birth (scheme II; months 0, 1 and 6). No serious adverse 
reactions were observed; 2.5% of the vaccinated newborns suffered mild transient 
local symptoms. The vaccine was highly immunogenic irrespective of vaccination 
scheme; all infants developed anti-HBs levels <: 10 IU/L, 97% <: 100 IU/L. The 
immunogenicity of hepatitis B vaccine after primary- and booster- vaccinations, 
administered in the four-dose scheme started at birth was significantly (p < 0.05) 
higher than in the three-dose scheme started at birth. Hepatitis B vaccination 
according to the four-dose scheme started at month 3 produced significantly (p < 
0.05) higher antibody levels in comparison to the four-dose scheme started directly 
after birth. This study showed that a four-dose hepatitis B vaccination scheme 
starting at month 3 resulted in the highest antibody levels of the three schemes 
investigated and can be recommended for incorporation into the Expanded 
Programme on Immunization in the Netherlands. 
Key words: hepatitis B vaccine, immunogenicity, neonates 
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Introduction 
The WHO strategy for the control of hepatitis B virus (HBV) infection and 
its sequelae, chronic hepatitis, cirrhosis and hepatocellular carcinoma, is mass 
vaccination of infants and young children within the framework of the WHO 
Expanded Programme on Immunization (EPI) (Ghendon 1990). Plasma-derived 
hepatitis B vaccine (PDV) has proven to be safe, effective and immunogenic in 
newborns for almost ten years (Beasley et al., 1983; Coursaget et al., 1986). Since 
the introduction of hepatitis B recombinant DNA vaccine, the vaccine became 
widely available. Clinical trials with the recombinant DNA yeast-derived hepatitis 
B vaccine (YDV), Engerix-B, manufactured by SmithKline Beecham Biologicals 
were started in 1984 to determine its safety, efficacy and immunogenicity in 
humans. Initial trials carried out with young adults indicated that YDV is safe and 
immunogenic in man and that it is comparable to PDV in terms of safety and 
immunogenicity (Scheiermann et al., 1987; Goudeau et al., 1987). Later on clinical 
trials involving three groups with a high risk for hepatitis B infection, i.e. the 
institutionalized mentally handicapped, homosexual men and neonates of hepatitis 
B surface antigen and e antigen (HBsAg, HBeAg) positive mothers, showed that 
YDV is safe, highly immunogenic and effective since the rate of hepatitis B 
infection was reduced to less than 5% (Damme Van et al., 1989; Goilav et al., 
1990; Poovorawan et al., 1990). Engerix-B was licensed in the Netherlands in 
1987. The established dose of Engerix -B vaccine used for neonates of HBsAg-
positive mothers in the Netherlands is 20 fig and the vaccine is given according a 
four-dose scheme at 3, 4, 5 and 11 months, together with the diphtheria-tetanus-
pertussis-polio (DTPP) vaccine (Anonymous, 1989). In other countries, however, 
the recommended three-dose scheme is started soon after birth, using only half the 
dose: I 0 fig (Centers for Disease Control, 1990). Until now, no studies on admini-
stration of the adult (20 fig) dose of Engerix-B to neonates of HBsAg-negative _ 
mothers have been published. Therefore we compared the immunogenicity of 20 
fig Engerix-B YDV administered in two four-dose vaccination schemes starting 
either at month 3 or at birth. We also compared a four-dose scheme with a three-
dose scheme, both starting at birth. 
Methods 
Subjects and randomization 
All pregnant women attending the prenatal clinic of the University Hospital 
Dijkzigt Rotterdam, the Netherlands, were screened for the presence of HBsAg at 
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their first visit, together with the lues and blood group serology. HBsAg-negative 
mothers were informed about the current hepatitis B immunization programme. 
Informed consent was obtained from the mother for the participation of her infant. 
Country of birth and age of the mother, gestational age, birthweight and sex of the 
child were registered on the parturition form. To be accepted in the study, 
newborns had to weigh at least 2000 grs at birth and have a 5-minutes Apgar score 
of 7 or higher. 180 newborns were randomised into three groups (groups 1-3), 
according to Peto (Peto et al., 1976). 18 children did not start the study for the 
following reasons: secondary refusal of the parents (n=13), delivery outside the 
trial area (n=3), birthweight less than 2000 grs (n=1) and multiple congenital mal-
formations (n=l). 51 neonates of group 1, 56 of group 2 and 55 of group 3 entered 
the study (intention to treat). 
Vaccine and vaccination-schemes 
The recombinant DNA yeast-derived hepatitis B vaccine was provided by 
SmithKline Beecham Biologicals (Engerix-B, Rixensart, Belgium). The vaccine 
was ad and ay antigenic and 20 f(g HBsAg were contained in 1.0 ml in single dose 
vials (lot numbers 163A4, 189A4, 199A4). The production, quality control and 
physiochemical characteristics of Engerix-B have been described elsewhere (Wilde 
De et al., 1985; Peetermans et al., 1987). Vaccine was always stored at 2 - 8 'C 
and administered into the quadriceps muscle by a physician. Parents were asked to 
record any local (soreness, redness, swelling) or systemic (fever >37.5 'C, gastro-
intestinal symptoms, fatigue) symptoms during three days following each injection 
of vaccine. 51 neonates of group 1 received four doses of vaccine at months 3, 4, 5 
(primary) and 11 (booster) -scheme I-; 56 neonates of group 2 received three doses 
of vaccine at months 0, 1 (primary) and 6 (booster) -scheme II- and 55 neonates in 
group 3 received four doses of vaccine at months 0, 1, 2 (primary) and 11 (booster) 
-scheme III-. 
Blood tests and laboratory methods 
2 ml of blood were obtained at month 0 (umbilical cord blood) and months 
4, 6, 11 and 12 in group 1; at months 3, 6, 7 and 12 in group 2 and at months 3, 6, 
11 and 12 in group 3. 
HBsAg, anti-HBc and anti-HBs were measured by radioimmunoassay 
(Ausria ll, Corab, Ausab, Abbott Laboratories Chicago USA). Anti-HBs is 
expressed in International Units/Litre (IU/L) after comparison with the WHO 
standard preparation (Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Services, Amsterdam, the Netherlands). 
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Table I. Distribution of the entry-variables by vaccination in groups 1, 2 and 3. 
Scheme II III P value 
Number of infants (N) 51 56 55 
Median gestational age (weeks) 40 40 40 0.92* 
Median birthweight (grams) 3330 3340 3240 0.40* 
Sex of child: (N) 0.16t 
Males 33 34 26 
Females 18 22 29 
Anti-HBs positive (N) 14 10 8 o.nr 
Anti-HBc positive (N) 10 10 7 0.61t 
Median age mother (years) 29 28 30 0.07* 
Country of birth mother: (N) 0.36t 
Netherlands 22 24 28 
Mediterranean 9 7 4 
Surinam 12 14 12 
Asian 0 2 5 
Miscellaneous 8 9 6 
* Kruskal Wallis test 
t Chi-square test 
Statistics 
Statistical analysis was performed on two data sets: data according to 
intention-to-treat data and clean data (data of all children who entered the study 
and were vaccinated and assessed according to the protocol). Differences in 
discrete variables were analysed by the Chi-square test. Continuous variables were 
analysed by the Kruskal Wallis test and the two-sample Wilcoxon rank sum test for 
unpaired observations. Geometric mean anti-HBs levels (GMT) are expressed in 
!U/L with 95% confidence intervals (CI). 
Results 
From September 1988 to March 1990, 162 infants born of HBsAg-negative 
mothers entered the study. After primary vaccination serum samples were available 
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in 45 (88%), 54 (96%) and 53 (96%) cases in scheme I, II and III, respectively. 
Mter boostervaccination, these figures were: 42 (82% ), 51 (91%) and 48 (87%). 7 
children discontinued the study, 1 child due to bad compliance with the 
vaccination scheme and 6 parents refused further cooporation. Clean data are 
based on 155 children. Statistical comparison of clean data with intention-to-treat 
primary vaccination booster vaccination 
nM45 n~$4 n~53 n~42 n~51 n~48 
2 3 2 3 
groups 
anti· HBs 
D >=0 lUlL ~ >=100 IU/L 
[2] >"'10 IU/L II >"'1000 lUlL 
Figure 1. Percentage of infants with various 
anti-HBs levels after primary- and booster-
vaccination with 20 )..lg Engerix-B hepatitis B 
vaccine accordi1tg to scheme 1: 3, 4, 5, 11 
months; scheme II: 0, 1, 6 months and scheme 
Ill: 0, 1, 2, 11 months. 
Anti-HBs seroconversion rate 
data did not reveal significant differen-
ces. The results of analysis of the clean 
data are presented below. There were no 
significant differences in country of 
birth of the mother, median age of the 
mother, median gestational age, median 
birthweight, sex of the child and number 
of infants with anti-HBs positivity and 
anti-HBc positivity in cord blood be-
tween the three groups (table 1 ). 
Passive transfer of maternal anti-
bodies 
Passively acquired anti-HBs positivity 
rates in cord blood were 27% (n=14), 
18% (n=lO) and 15% (n=8) for group 1, 
2 and 3, respectively. Anti-HBc posi-
tivity rates at birth were 20% (n=10), 
18% (n=lO) and 13% (n=7), respectively. 
In all cases anti-HBc became negative at 
month 12. 
Figure 1 shows the frequences of protective levels of anti-HBs levels after 
primary- and booster-vaccination in the three different vaccination schemes. An 
anti-HBs level " 10 IU/L is assumed to be protective against hepatitis B. All 
infants who received the first vaccination at month 3 (scheme I), developed anti-
HBs levels" 10 IU/L after primary vaccination. All infants who started vaccination 
at birth (scheme II and III), developed anti-HBs levels ;, 10 IU/L, but in 11 cases 
this did not occur until after the booster vaccination. As far as long-term protection 
is concerned, all infants from group 1 and 3 had anti-HBs levels ;, 100 IU/L after 
the booster vaccination. Whereas in group 2, this corresponding percentage 
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amounts only 92 (47/51). 98% of the infants in group 1 and 3 had anti-HBs titre"' 
1000 !U/L after the booster vaccination in comparison with 76% of the infants in 
group 2. 
The anti-HBs levels for 8 children in scheme II (15%) and 3 children in 
scheme III (6%) were < 10 IU/L after primary vaccination (month 3). After the 
booster vaccination 6 of these children exhibited more than 1000 IU/L, 3 between 
100 and 1000 !U/L and 2 between 10 and 100 IU/L. 
Table 2 lists the anti-HBs levels (GMT) with 95% CI (anti-HBs > 0 !U/L) 
for the three different schemes. The GMT anti-HBs after primary vaccination and 
after booster vaccination with 4 doses for scheme I, which started at month 3, were 
264 IU/L and 20768 IU/L, respectively. This is significantly (Wilcoxon test: P 
value 0.004 and 0.01, respectively) higher than those for scheme III, which started 
at birth, i.e., 135 IU/L and 10495 IU/L, respectively. Comparison of the groups 
receiving 3 and 4 doses, both started at birth, shows that the GMT anti-HBs after 
primary- and booster-vaccination in four-doses (scheme Ill) were significantly 
(Wilcoxon test: P value 0.004 both) higher than those after 3 doses (scheme II): 56 
IU/L and 3090 IU/L, respectively. 
Table 2. Immunogenicity after primary~ and booster- vaccination with 20 ~g Engerix-B hepatitis B 
vaccine according to three schemes varying in number of doses and time of immunization. 
Scheme Month anti-HBs 95% CI P value 
(>0 IU/L) 
(GMT) 
1-2 months after primary vaccination 
I (3, 4, 5, ll) 6 264 157-444 
II (0, 1, 6) 3 56 44-106 0.004* 
Ill (0, 1, 2, ll) 3 135 87-221 0.004t 
1 month after booster vaccination 
(3, 4, 5, !1) 12 20768 14714-29312 
II (0, 1, 6) 7 3090 1830-5218 0.004* 
Ill (0, 1, 2, 11) 12 10495 7332-15023 o.o10t 
* Wilcoxon test scheme I versus II 
t Wilcoxon test scheme I vesus III 
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No significant differences in GMT anti-HBs were found between boys and 
girls, presence of passively acquired maternal antibodies (anti-HBs, anti-HBc) and 
various countries of birth of the mother. Of the 32 infants with passively acquired 
anti-HBs at birth (GMT anti-HBs at month 0: 333 IU/L, 95% CI: 140-798 IU/L), 
31 exhibited at least one increase in the anti-HBs titre after vaccination, only one 
did not. 
Adverse reactions to vaccine 
No cases of clinical hepatitis or serious side-effects of the vaccine were re-
ported. In four cases (2.5%) the parents of the vaccinated children reported 
transient soreness at the site of injection. No fever was noted in groups 2 and 3 
(after the first three doses). Most children in group 1 received DTPP vaccination 
synchronous with the hepatitis B vaccination. Due to the relatively frequent 
occurrence of fever, a side-effect known of DTPP vaccination, we were not able to 
evaluate the fever observed in group 1. 
Discussion 
The 20 flg Engerix-B hepatitis B vaccine used in this study was safe and 
highly immunogenic in all 3 vaccination schemes. No serious side-effects were 
reported. In only 2.5% of the infants mild transient local symptoms were present; 
this finding is in agreement with earlier results (Poovorawan et al., 1990). All in-
fants reached anti-HBs levels;, 10 IU/L, 97% " 100 IU/L, after completion of the 
vaccination scheme (figure 1). An anti-HBs level ;, 10 IU/L is assumed to be pro-
tective against HBV infection (Szmuness et al., 1981) and an anti-HBs level " 100 
IU/L is taken as evidence of long-lasting immunity (Hadler et al., 1986). The anti-
HBs level (GMT) at month 6 in our study is comparable to the concentration anti-
HBs at month 6 in an earlier study, in which 20 flg Engerix-B YDV was adminis-
tered to neonates of HBsAg-positive mothers in 3 doses at months 0, 1 and 2, with-
out hepatitis B immunoglobuline (HB!g) administration (Cadranel et al. 1987). The 
immunogenicity demonstrated in our study was 3 times higher than that reported in 
a corresponding study in which only half of the dose (10 flg) of Engerix-B YDV 
was used (Poovorawan et al., 1990); it was similar to the acquired anti-HBs con-
centration reported for healthy adults receiving the full 20 flg dose of Engerix-B 
YDV (Scheiermann et al., 1987). The recommended dosage of vaccine for neo-
nates is ambiguous; the Dutch authorities advises a full dosage of 20 flg Engerix-B 
YDV (Anonymous, 1989), the Immunization Advisory Committee recommends 
half of this standard adult dosage (10 ftg) (Centers for Disease Control, 1990). The 
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duration of immunity after hepatitis B vaccination is currently unknown but it is 
generally assumed that the higher the antibody levels after vaccination, the longer 
the period of protection (Hadler et al., 1986; Jilg et al., 1987; Scheiermann et al., 
1990). The vaccine was highly immunogenic in all 3 schemes investigated. For 
reasons of compliance it seems favourable for health authorities to opt for that 
scheme which can be incorporated into the existing EPI programme. In this study, 
Engerix-B YDV administered according to 2 four-dose schemes produced higher 
immunogenicity than YDV in three doses. If the finances and logistics allow it, a 
four-dose scheme and a full dosage of Engerix-B YDV seem preferable in coun-
tries where this vaccination scheme can easily be incorporated into the existing EP! 
programme (as in the Netherlands). Engerix-B YDV according to a four-dose 
scheme starting at month 3 yields a significantly higher immunogenicity than YDV 
in four doses starting at birth. This finding confirms results from our previous stu-
dies of 4 doses PDV in newborns of HBsAg-positive mothers (Schalm et al., 
1989). This may be explained by the more mature immune system in children 
receiving their first vaccination later. Since we know that the efficacy of the com-
bination of HB!g and hepatitis B vaccine is much greater than hepatitis B vaccine 
alone in preventing perinatal hepatitis B infection (Beasley et al., 1983), it is im-
portant that the children of HBsAg-positive mothers are covered with HB!g in the 
period between birth and active hepatitis B vaccination. In countries where HB!g is 
not sufficient and/or screening- programmes are not available, the decision to vac-
cinate against hepatitis B at birth or to wait and give the first dose together with 
other routine immunizations may only be taken after assesment of the risk to the 
infant of early infection, a risk which varies from region to region. Advancement of 
the starting date for other vaccinations (such as DTPP) in these countries, if future 
studies prove that this is feasible, might also contribute to a solution. For the grea-
test possible compliance, incorporation into the existing immunization programme 
is very important, despite the lack of a recommended optimal strategy for the admi-
nistration of hepatitis B vaccine. Another obstacle to establishment of these recom-
mendations is the wide variety of vaccination schemes of the EPI programme in 
different parts of the world, even in Europe. After the publication of a study, in 
which the immune response to YDV did not interfere with the immune response to 
either diphtheria and tetanus toxoids or oral polio vaccine (Giammanco et al., 
1991), Italy started a compulsory hepatitis B vaccination programme for all new-
borns in May 1991. Recently health authorities opted for mass hepatitis B vacci-
nation of all newborns in countries where the overall HBsAg carrier rate exceeds 
1% and the HBV markers occur in 10 to 20 per cent of the population (as in Italy); 
screening and selective vaccination are recommended for countries with a HBsAg 
carrier rate below 0.5% and HBV markers in 5 to 10 per cent of the population (as 
in France and the Netherlands) (Goudeau et al., 1990). In the Netherlands, where 
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until now only the high-risk population is screened and vaccinated, the HBsAg 
carrier rate is estimated at 0.8% (Schalm et al., 1989) but in the present study the 
anti-HBs and anti-HBc positivity rates for HBsAg-negative mothers were between 
15 and 30 per cent, much higher than expected. It should be noted however that the 
population investigated included a lot of immigrants and is not fully representative 
of the Dutch population (table 1). It will depend on the (political) strategy of the 
health authorities whether or not mass hepatitis B vaccination will be initiated. The 
costs of new vaccines such as the combination DTPP-hepatitis B vaccine, as well 
as the results of studies on long-term vaccine efficacy to determine if and when 
booster doses will be needed will play a role in these decisions. Perhaps increased 
consultation between health authorities in Europe will lead to a decrease in the 
number of existing vaccination schemes and thus open the way for recommenda-
tions that will lead to the eradication of hepatitis B. 
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Abstract 
The immunogenicity of one half (5 11g) and a full (10 11g) dosage of 
recombinant DNA yeast-derived hepatitis B vaccine (HB-Vax-DNA) in healthy 
neonates was assessed in order to compare two candidate dosages of vaccine. After 
randomization 174 newborns of HBsAg-negative mothers entered the study. 
Neonates received 4 doses of either 10 1-1g or 5 11g hepatitis B vaccine, according to 
the DTP-polio immunization schedule at months 3, 4, 5 and 11. No serious adverse 
reactions were observed; 15.5% of vaccinated newborns suffered mild transient 
local symptoms. The vaccine was highly immunogenic irrespective of dosage of 
vaccine; all infants developed anti-HBs levels" 10 IU/L, 99%" 100 IU/L. 
Ten 11g hepatitis B vaccine produced higher antibody levels than 5 11g 
hepatitis B vaccine after primary vaccination (first three doses) but not after 
booster vaccination (fourth dose) (p = 0.06 and 0.75, respectively). Both vaccine 
dosages can be recommended for incorporation in the Expanded Programme on 
Immunization in the Netherlands. 
Keywords: hepatitis B vaccine, immunogenicity, neonates. 
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Introduction 
The WHO strategy for the control of hepatitis B virus (HBV) infection and 
its sequelae, chronic hepatitis, cirrhosis and hepatocellular carcinoma, is mass 
vaccination of infants within the framework of the WHO Expanded Programme on 
Immunization (EPI) (1). In 1982 plasma-derived hepatitis B vaccine was licensed 
in the Netherlands and a vaccination programme to determine an effective and 
practical immunization schedule for the prevention of hepatitis B in neonates of 
HBsAg positive mothers was initiated (2). More than 95% of infants developed 
protective levels of anti-HBs after passive active immunization (2). The most 
effective and immunogenic schedule was achieved with 4 adult doses of vaccine 
(10 fig HB-Vax-DNA, Merck Sharp & Dohme, West Point, USA), starting at 3 
months of age concomitant with DTP-polio immunization (2,3). Higher antibody 
levels were obtained after administration of 3 adult doses of 10 fig HB-Vax-DNA 
(GMT anti-HBs at month 12: 1236 IU/L) than after 3 infant doses of 5 fig HB- Vax-
DNA (GMT anti-HBs at month 12: 510 lU/L), both starting directly after birth (3). 
An anti-HBs level" 10 IU/L is assumed to be protective against HBV (4) and an 
anti-HBs level " 100 IU/L ensures a long-lasting immunity (5). HB-Vax-DNA 
recombinant hepatitis B vaccine, manufactured by Merck Sharp & Dohme 
Laboratories, was licensed in the Netherlands in 1987. Until now, no studies on the 
administration of adult and infant doses of HBvax-DNA recombinant hepatitis B 
vaccine, administered at months 3, 4, 5 and 11 to neonates of HBsAg-negative 
mothers, have been performed. Therefore we compared the immunogenicity of 10 
fig and 5 fig HB- Vax-DNA recombinant hepatitis B vaccine administered 
according to a four-dose schedule, starting at month 3. 
Methods 
Subjects and randomization 
All pregnant women attending the prenatal clinic of the University Hospital 
Dijkzigt Rotterdam, the Netherlands, were screened at their first visit for the presence 
of HBsAg, as well as their blood group /rhesus factor and screening for syphilis. 
HBsAg -negative mothers were informed about the current hepatitis B immunization 
programme. Informed consent was obtained from the mother for the participation of 
her infant. Country of birth and age of the mother, gestational age, birthweight and 
sex of the child were registered on the parturition form. To be accepted into the study, 
newborns had to weigh at least 2000 grs at birth and have a 5-minute Apgar score of 
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7 or higher. In total214 newborns were randomized into groups I and II, according to 
Peto (6). Forty children were not included in the study for the following reasons: 
secondary refusal of the parents (n=30), birthweight less than 2000 grs (n=4), Apgar 
score less than 7 (n=5), perinatal death (n=l). As a result, 86 neonates of group I and 
88 of group II entered the study (intention to treat). 
Vaccine and vaccination-schemes 
The ad antigenic recombinant DNA yeast-derived hepatitis B vaccine was 
provided by Merck Sharp & Dohme (10 f.!g and 5f.lg HB-Vax-DNA, Westpoint, 
USA); 10 f.!g HBsAg were contained in 1.0 ml, 5 f.lg HBsAg in 0.5 ml, both in 
single dose vials (lot numbers 496750P, 557860P, 5806990S, 609540S, 651450S for 
10 f.lg HB-Vax-DNA and 460201N, 460202N, 088011CH-B, 580700S, 623040S, 
676710T for 5 f.!g HB-Vax-DNA). The production, quality control and physiochemi-
cal characteristics of HB-Vax-DNA have been described elsewhere (7). The 
vaccine, always stored at 2-8 oc, was administered into the quadriceps muscle by a 
physician. Parents were asked to record any local (soreness, redness, swelling) or 
systemic (fever > 37.5 oe, gastrointestinal symptoms) symptoms during three days 
following each injection of vaccine. Concomitant side-effects to be due to DTP-
polio immunization given at the same time were excluded from analysis. The 86 
neonates of group I received four doses of 10 ftg vaccine and 88 neonates of group 
II received four doses of 5 f.lg vaccine. The vaccine was administered in both groups 
at months 3, 4, 5 (primary vaccination) and 11 (booster vaccination). 
Blood tests and laboratory methods 
Two ml of blood were drawn at month 0 (umbilical cord blood) and months 
4, 6, 11 and 12 in both groups. 
HBsAg, anti-HBc and anti-HBs were measured by radioimmunoassay 
(Ausria ll, Corab, Ausab, Abbott Laboratories Chicago, USA). Anti-HBs is 
expressed in International Units/Litre (lUlL) after comparison with the WHO 
standard preparation (Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Services, Amsterdam, the Netherlands). 
Statistics 
Statistical analysis was aplied on two data sets: data according intention-to-
treat data and clean data (data of all children who entered the study and were 
vaccinated and assessed according to the protocol). Results between "intention to 
treat data" and "clean data" did not differ. The results of analysis of the clean data 
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Table 1. Distribution of the entry-variables according to vaccination groups I and II. 
Group I II P value 
Number of infants (N) 86 88 
Median gestational age (weeks) 40 39 0.20* 
Median birthweight (grams) 3323 3218 0.16* 
Sex of child: (N) 0.76** 
Males 51 50 
Females 35 38 
Anti-HBs positive (N) 11 13 0.83** 
Anti-HBc positive (N) 10 1 1.00** 
Median age mother (years) 26 29 0.20* 
Country of birth mother: (N) 0.45*** 
Netherlands 28 23 
Mediterranean 12 17 
Surinam 29 25 
Asian 1 4 
Miscellaneous 16 19 
* Wilcoxon Ranksum test 
** Fisher's exact test 
***Chi-square test 
are presented below. Differences in discrete variables were analysed by Fisher's 
exact test and Chi-square test. Continuous variables were analysed by the two-
sample Wilcoxon Rank sum test for unpaired observations. Limit for significance 
was set at 0.05. Geometric mean anti-HBs levels (GMT) are expressed in IU/L 
with 95% confidence intervals (CI). 
Results 
From April1990 to March 1992, 174 infants born of HBsAg-negative mothers 
entered the study and were vaccinated according to the protocol. After primary 
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Figure 1. Percentage of infants with various anti-
JJBs levels after primary- and booster- vaccination 
with 10 f.A.g and 5 f).g HB- Vax-DNA hepatitis B 
vaccine administered at months 3, 4, 5 and 11 
months of age. 
Anti-HBs seroconversion rate 
vaccination serum samples were ob-
tained in 73 (85%) and 79 (90%) cases 
in group I and II, respectively. After 
booster vaccination, 66 (77%) and 77 
(88%) samples were available. There 
were no significant differences in coun-
try of birth of the mother, median age of 
the mother, median gestational age, 
median birthweight, sex of the child and 
number of infants with anti-HBs 
positivity and anti-HBc positivity in 
cord blood between the two groups 
(table 1). 
Passive transfer of maternal anti-
bodies 
Passively acquired anti-HBs 
positivity rates for cord blood were 
13% (n=ll) and 15% (n=13) for 
groups I and II, respectively. Anti-HBc 
positivity rates at birth were 12% (n=-
10) and 13% (n=ll), respectively. In 
all but one case anti-HBc was negative 
at month 12 (in 1 case the test result 
was not available). 
Figure 1 shows the frequencies of protective levels of anti-HBs levels 1 
month after primary and booster vaccination in the two groups. All infants who 
received 10 1-lg of vaccine (group I) developed protective anti-HBs levels (;, 10 
IU/L) after primary vaccination. All infants who received 5 1-lg of vaccine (group 
II) developed anti-HBs levels " 10 IU/L, but in 2 cases this did not occur until after 
the booster vaccination. As far as long-term protection is concerned, 100% of 
infants in group I had anti-HBs levels " 100 IU/L after the booster vaccination; for 
group II the corresponding percentage was 99%; one child had an anti-HBs level 
between 10 and 100 IU/L. Ultimately 88% of the infants in group I had anti-HBs 
levels " 1000 IU/L after the booster vaccination in comparison to 90% of the 
infants in group II. 
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The anti-HBs level for 2 children in group II were 1 IU/L and 6 IU/L, 
respectively, after primary vaccination, After the booster vaccination these 
childeren exhibited 64 and 8078 IU/L, respectively. 
Table 2 lists the anti-HBs levels (GMT) with 95% CI (anti-HBs > 0 IU/L) 
for the two different schedules. The GMT anti-HBs, obtained 1 month after 
primary vaccination and after booster vaccination with 4 doses of 10 etg HB-Vax-
DNA were 23I IU/L and 4119 IU/L, respectively. This tends to be significantly 
(Wilcoxon test: p = 0.06) higher than those found for infants in group II after 
primary vaccination (GMT anti-HBs: 137 IU/L) but not (Wilcoxon test: p = 0.75) 
after booster vaccination (GMT anti-HBs: 3823 IU/L). 
Anti-HBs levels at month 24 were available for 32 infants of group I (GMT 
anti-HBs 290 IU/L, 95% CI: 187-449) and 36 infants of group II (GMT anti-HBs 
231 IU/L, 95% CI: 138-386). 
No significant differences in GMT anti-HBs were found between boys and 
girls, presence of passively acquired maternal antibodies (anti-HBs, anti-HBc) and 
various countries of birth of the mother. 
Adverse reactions to vaccine 
No cases of clinical hepatitis or serious side-effects of the vaccine were 
reported. In 27 cases (15.5%) the parents of the vaccinated children reported 
transient red swelling at the site of injection or fever (less than 39 °C). No 
significant differences in the amount of side-effects between infants in group I and 
group II were found. 
Table 2. Immunogenicity 1 month after primary and booster vaccinations with 10 [lg and 5 !J,g IfB- Vax-
DNA hepatitis B vaccine administered at 3, 4, 5 and 11 months. 
group No month anti-HBs 95% CI P value 
(> 0 lUlL) 
(GMT) 
1 month a(!er wimar~ vaccinatiQJl 
I (10 [kg) 73 6 231 163-328 0.06" 
II (5etg) 79 6 137 99-190 
1 month a(!er booster vaccination 
I(10etg) 66 12 4119 3064-5538 0.75" 
II (5 [kg) 77 12 3823 3008-4859 
a Wilcoxon test scheme I versus II 
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Table 3. Immunogenicity of at least 3 doses of hepatitis B recombinant vaccine (HB- Vax-DNA, Merck 
Sharp & Dohme) in healthy neonates and infants. 
Author Dose Scheme No of Age-group Sera- GMT anti-HBs 
(year (~g HBsAg) in months vaccinees (neonates conversion of converters 
public.) mother rate(%)' (95 %Cl)' 
I-IDsAg +/-) 
Lai ('86) 5 0, I and 6 21 infants 1002 1894 (?) 
neonates+ 
Stevens ('87) 5 0,1and6 83 neonates+ 1006 307 
Milne ('88) 10 O,land6 56 infants 982 3246 (2272-4636) 
5 0, 1 and 6 60 982 2305 (1638-3158) 
2.5 0,1and6 56 982 1370 (866-2169) 
Stevens ('90) 5 0, 1, 2 and 6 94 neonates+ 963 509 
Goh ('92) 5 0, 1 and 6 31 infants 1003 1699 (?) 
2.5 0, I and 6 30 933 1689 (?) 
1.25 O,land6 29 1003 1135 (?) 
0.6 0,1and6 31 953 1088 (?) 
Canho del 10 3, 4, 5 and 11 65 neonates- 100' 4119 (3064-5538) 
(present study) 5 3, 4, 5 and 11 71 neonates - 100' 3823 (3008-4859) 
"'1 (1), 2 (2), 3(3) or 6(6) months after completion of vaccination scheme 
Discussion 
The 10 [-lg and 5 [-lg HB-Vax-DNA hepatitis B vaccines used in this study 
were safe and highly immunogenic. No serious side-effects were reported. In 
15.5% of the infants mild transient local symptoms were present, irrespective of 
the dose of vaccine. This finding is in agreement with earlier results (8,9). 
All infants reached anti-HBs levels " 10 IU/L, 99% " 100 IU/L, after 
completion of the vaccination schedule (figure 1 ). In table 3 the results of different 
studies on the immunogenicity of at least 3 doses of recombinant hepatitis B 
vaccine (MSD) in healthy neonates and infants are listed. Although there is 
accordance in the seroconversion rates, the GMT anti-HBs differs (median 1694 
IU/L, range 307-4119 IU/L). These differences might be explained by differences 
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in maternal HBsAg status, vaccine, dose, schedule, time of blood sampling, age 
and ethnic background of the vaccinees. 
In comparison with a full dosage (20 ftg) of Engerix-B recombinant hepatitis 
B vaccine (SmithKline Beecham Biologicals) administered at months 3, 4, 5 and 
11 to neonates of HBsAg-negative mothers (10), GMT anti-HBs at months 12 and 
24 were 20768 IU/L and 2957 !U/L, respectively, 5 and 10 times higher than those 
obtained with 10 ecg HB-Vax-DNA in the present study. The seroconversion rate 
for 20 ecg Engerix-B recombinant vaccine (SKB) was the same as that for 10 ecg 
HB-Vax-DNA recombinant vaccine (MSD), both being 100% (10). In another 
study four doses of 10 ecg Engerix-B resulted in GMT anti-HBs of 2565 IU/L one 
month after the fourth dose, which is 1.5 times lower than in the present study; the 
seroconversion rate was 97.1% (11). 
Our previous study (2) with 10 ecg plasma vaccine (MSD), administrated at 
months 3,4,5 and 11, showed that plasma vaccine gives a significantly higher 
(Wilcoxon Rank-sum test p = 0.0001) anti-HBs response (n=99, peak level at 
month 12: 13427 IU/L) than 5 and 10 ecg of the recombinant vaccine evaluated in 
the present study (n=143, peak level groups I and II at month 12: 3957 IU/L). This 
finding is in agreement with previous studies (12, 13). The proportional decline in 
anti-HBs between 12 and 24 months was not significantly different (Wilcoxon 
Rank-sum test p=0.3572) between plasma vaccine (91 %, 95% CI: 21-98) and 
recombinant vaccine (91 %, 95% CI: 71-98). This is in agreement with the study of 
Jilg eta!. (14), who found a 90% reduction in anti-HBs, 12 months after the last 
vaccination with 20 ecg, 10 ecg and 5 ecg plasma vaccine. However more long-term 
immunogenicity studies on recombinant hepatitis B vaccine are needed to 
determine whether the decline of antibodies resembles that for plasma hepatitis B 
vaccme. 
The recommended dosage of vaccine for neonates is ambiguous; Dutch 
authorities advise a full dosage of 10 ecg HB-Vax-DNA (15); the Immunization 
Advisory Committee recommends half this standard adult dosage, 5 ecg (16). 
Recently, 2 ecg and 2.5 [Ag doses of HB-Vax-DNA were recomended for the 
national childhood immunization programme because no significant differences in 
seroconversion rates could be found between 2.5 ecg, 5 [Ag and 10 ecg HB-Vax-
DNA, administered at months 0, 1 and 6 to anti-HBs negative infants, after 
completion of the vaccination schedule (17, 18). Much lower dosages of 0.6 ecg and 
1.25 ecg HB-Vax-DNA were even as immunogenic as 2.5 ecg, but not before month 
9 (18). We found that 5 ecg HB-Vax-DNA builds up a lower anti-HBs level than 10 
ecg HB-Vax-DNA after primary vaccination but that difference disappears after the 
booster vaccination. 
The conclusion is that lower dosages of vaccine require more time to build 
up the same immunogenicity. For universal vaccination of infants of HBsAg-
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negative mothers the rapidity of acquiring the required immunogenicity is less 
important than for infants of HBsAg-positive mothers, who are at greatest risk for 
HBV. 
It appears that health authorities must opt for that vaccine dosage that will 
satisfy the task they set up. 
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Abstract 
From 1982-1989, 705 infants born to HBsAg positive mothers entered the 
Dutch neonatal hepatitis B vaccination program and received passive-active hepati-
tis B immunization, according to 6 schedules, varying in time of onset vaccination, 
dose of hepatitis B immunoglobulin (HB!g) and type and dose of vaccine. 118 
(17%) of the mothers were also HBeAg positive. This final report describes the 
protective efficacy and long-term immunogenicity of passive-active hepatitis B 
immunization over a period of 10 years. 
During follow up, 9 infants became HBsAg carriers; 8, all born to HBeAg 
positive mothers within the first year and another child, born to an HBeAg negative 
mother at the age of 5 years. No evidence of emergence of escape hepatitis B 
mutants was found. Protective Efficacy Rate (PER) of passive-active hepatitis B 
immunization at 12 months follow up was 92% for the total group with no 
significant differences between groups starting active immunization at birth or at 3 
months; groups receiving one or two doses of HB!g or groups receiving plasma-
derived or recombinant vaccine. The PER at month 12 in the group with maternal 
HBV-DNA levels less than 150 pg/ml was 100% and significantly higher than the 
68% for the group with HBV-DNA levels above 150 pg/ml. 
After 5 years of follow up, the group with active hepatitis B immunization 
star.ting at birth had significantly more infants with anti-HBs levels less than 10 
IU/L (15%) than the corresponding group starting at 3 months (2%). Geometric 
Mean Titres of anti-HBs were significantly higher in the group, starting at 3 
months of age with plasma vaccine than in the corresponding group receiving 
recombinant vaccine. 
This program showed that passive-active hepatitis B vaccination can be 
highly effective in the prevention of neonatal hepatitis B, except for children born 
to women with high hepatitis B viraemia. Evaluation of vaccine schedules should 
taken into account risk assessment according to maternal HBV-DNA levels. The 
excellent efficacy of delayed active vaccination allows incorporation of hepatitis B 
vaccine into the standard infant immunization programs for countries with a pas-
sive-active immunization strategy for hepatitis B. For long-term protection, dosage 
of recombinant vaccine with equal immunogenicity to that of plasma vaccine 
should be considered. 
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Introduction 
Passive-active immunization with hepatitis B immunoglobulin (HB!g) and 
hepatitis B vaccine has proven to be highly effective in preventing perinatal 
transmission of hepatitis B infection for more than a decade (1-3). 
These studies were performed in infants born to HBeAg positive mothers, 
who are considered at nearly 90% risk for developing chronic hepatitis B virus 
infection (1, 4-6). Recently the risk of maternal to infant transmission of HBV was 
shown to be related to the presence of HBV-DNA in serum of HBeAg carrier 
mothers (7 -9). The protective efficacy rate of passive-active hepatitis B immuni-
zation has not been assessed according to maternal HBV-DNA levels. 
When hepatitis B vaccine was licensed in The Netherlands in 1982, a pro-
gram was started to screen mothers for HBsAg positivity and to immunize their 
offspring. The vaccination program evaluated -in addition to various passive-active 
immunization schedules starting at birth- a schedule with passive immunization at 
birth and active immunization starting at 3 months of age, concomittant with 
Diphteria-Tetanus-Pertussis and Poliomyelitis (DTPP) vaccination. We hypo-
thesized that efficacy of delayed active immunization would be similar, but long-
term immunogenicity superior to immunization starting at birth. Such a result 
would allow incorporation of active hepatitis B immunization in the standard infant 
immunization program, which was thought to be advantageous with respect to 
logistics and costs. Preliminary results confirmed the hypothesis (1 0). 
With the introduction of recombinant vaccine (1987), confirmation was also 
needed for recombinant vaccine (11 ). This study also allowed testing the need for sup-
plementary hepatitis B immunoglobulins (HB!g) at the start of delayed active 
immunization. 
Our findings that within the population studied, vaccination failure is primarily 
related to high maternal HBV-DNA levels (12) made it necessary to reevaluate the 
effects of components of the various schedules; time of starting active immunization, 
types and doses of HB!g and vaccine used, in relation to maternal HBV-DNA levels. 
This final report of the Dutch program for prevention of perinatal hepatitis B 
describes the protective efficacy and long-term immunogenicity of passive-active 
hepatitis B immunization over a period of 10 years. 
Subjects and methods 
Hepatitis B screening 
The study was started in July 1982 in three large city hospitals in Rotterdam 
and Utrecht and one large rural area, Twente-Gelderse Achterhoek. Blood samples 
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taken from all pregnant women at their first visit to the prenatal clinic of the 
participating centers were tested for the presence of HBsAg, in addition to the 
routine determination of blood group/rhesus factor and screening for syphilis, In 
case of a positive finding for HBsAg, a repeat HBsAg test was performed at 28 
weeks of pregnancy. If HBsAg positivity was confirmed, randomization to one of 
the immunization schedules took place after informed consent was obtained from 
the mother. In the two participating hospitals in Rotterdam, the HBsAg status of 
expectant mothers was checked soon after arrival in the delivery room. Whenever 
prenatal HBsAg test results were missing, blood was obtained and tested the next 
morning with a rapid hemagglutination HBsAg test. If the rapid HBsAg test was 
positive, the mother was asked for informed consent and the baby was randomized 
and included in the immunization trial. All pregnant HBsAg positive women were 
also tested for the presence of HBeAg. In december 1992, maternal HBV-DNA le-
vels were quantified retrospectively in the available stored serum samples positive 
forHBeAg. 
Subjects and immunization schedules 
From July 1982-January 1988, 495 eligible babies were randomly allocated 
to one of the four plasma-vaccine immunization schedules (table 1: groups I-IV); 
from January 1988-0ctober 1989, another 210 eligible babies were allocated to one 
of the two recombinant-vaccine immunization schedules (table 1: groups V-VI). 
All infants received HB!g (200-300 IU, Central Laboratory of the Nether-
lands Red Cross Blood Transfusion Service, Amsterdam, the Netherlands) intra-
muscularly within two hours of birth by the physician or midwife in charge of the 
delivery. For active immunization, infants were referred to a pediatrician. Infants 
received plasma vaccine (10 ~g and 5 ~g HBvax, Merck Sharp & Dohme, West 
Point, USA) or recombinant vaccine (20 ~g Engerix-B, SmithKline Beecham, 
Rixensart, Belgium). Nine infants (1 in group II, 3 in group Ill and 5 in group IV) 
with an anti-HBs level ,; 10 IU/L at 12 months of age and a negative test for 
HBsAg received an additional course of plasma- or recombinant- vaccine in their 
second year of life (13). 
Serological assays and laboratory methods 
Blood samples were taken from the infants at birth (cord blood) and in groups 
I and II at months 3, 6, 11, 12, yearly until 9 years of age; in groups Ill and IV at 
months 3, 6, 12, yearly until5 years of age; in groups V and VI at months 3, 4, 6, 11, 
12 and at 2 years of age. All serum samples from the babies were tested for anti-HBs 
and anti-HBc; HBsAg was assayed in all samples with anti-HBs below 100 JU/L. 
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Table 1. Immunization schedules of study groups. 
Groups entry munbcr of infants HBig' vaccine 
period total (mother evaluated for evaluated for moths/dose type/dose 
HBeAg +) immunogcnicity cfficacy12 months after birth 
--
1982-1984' 117 (38)t 110 (35) 103 (37) 0/200 p1asmah 10 ~g 
11 1982-1984 121 (42) 109 (37) 105 (41) 0,3/200,120 plasma 10 ~tg 
lii 1984-1987' 133 (3) 128 (2) 127 (3) 0/200 plasma 10 ~g 
IV 1984-1987 124 (4) 122 (4) 115 (2) 0/200 plasma 5 ~g 
v 1988-1989 112 (14) 102 (13) 98 (14) 0/300 recomb.c 20 ~lg 
VI 1988-1989 98(17) 93 (17) 83(17) 0,3/300, 300 recomb. 20 ~g 
Total 1982-1989 705 (118) 664 (I 08) 631 (114) 
* Infant<> of HBeAg positive mothers entered in group I and II until december 1 !J87 
i" Between parenthesis number of infants with I-I BeAg positive mothers 
a Hepatitis B immunoglobulin, Central Laboratory of the Dutch Red Cross Blood Transfusion Service, Amsterdam, the Netherlands 
b HBvax, Merck Sharp & Dohme, Westpoint, USA 
c Engerix-B, SmithKline Beecham Biologicals, Rixensart., Belgium 
schedule 
months after 
birth 
0, 1, 2 and 11 
3, 4, 5 and 11 
0, 1, 6 
0, 1, 6 
3, 4, 5 and 11 
3, 4, 5 and 11 
HBsAg, HBeAg, anti-HBc and anti-HBs were assessed using a commercial 
radioimmunoassay kit (Abbott Laboratories, Chicago, ILL, USA), HBV-DNA 
quantitatively by a solution hybridization assay (HBV-DNA, Abbott Laboratories, 
USA). 
Definition of HBV infection 
A HBV carrier state was defined as being HBsAg positive for more than 6 
months. Transient HBV infection was characterised by being HBsAg positive less 
than 6 months. Inapparent HBV infection was defined as anti-HBc positive without 
HBsAg on two or more occasions after months 12. 
Statistical analysis 
Data available were analyzed according to intention-to-treat principle. 
Separate per-protocol analysis, i.e. analysis of data of children who received vacci-
nations according to protocol, were also performed. The outcomes of these 
analyses did not significantly differ. Therefore we report on the protective efficacy 
using outcomes of the intention-to-treat analysis (including infants who violated 
the protocol); the results on the immunogenicity are reported using the outcomes of 
the per-protocol analysis. 
Protection by different immunization schedules was expressed as the 
protective efficacy rate (PER) = 100% multiplied by (expected number of HBV 
infections without immunoprophylaxis minus measured number of HBV infections 
with immunoprophylaxis divided by the expected number of HBV infections 
without immunoprophylaxis). The expected number of HBV infections without 
immunoprophy !axis was estimated to be 90% of the number of infants from 
HBeAg positive mothers per immunization group (3-5). PER was also calculated 
for a percentage of 67 for expected number of HBV infections without immuno-
prophylaxis, in view of the finding that one third of HBeAg positive mothers of 
infants had a HBV-DNA level less than 5 pg/ml and therefore unlikely to transmit 
hepatitis B to their infants (8). 
To investigate whether patients with incomplete data affected the outcomes 
of the long-term immunogenicity, the percentages of infants with anti-HBs levels 
<10 IU/L were also calculated for the group of infants which had no missing data 
(excluding occasional missing data, that could be obtained by linear interpolation 
of 2 adjacent points). The percentages thus obtained differed at all time-points at 
most 4% of those given in figure 3, indicating that loss to follow up did not signifi-
cantly affect the outcomes as presented. 
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Differences in percentages were analysed by Chi-square test or Fisher's 
exact test in case of small numbers. Continuous variables were analysed by the 
two-sample Wilcoxon rank-sum test. Limit for significance was set to 0.05 (two-
sided). In case of evaluations at various timepoints, the limit of significance was set 
according to Bonferoni 's principle to allow for the multiplicity of statistical tests. 
Anti-HBs levels were expressed in IU/L. Geometric mean titers (GMT) were 
calculated only for those infants who had anti-HBs " 10 IU/L. Exact confidence 
limits for odds-ratio were calculated using the statistical software package 'STAT-
XACT'. 
Ethics 
The study was approved by the local Medical Ethics Committee of the 
participating centres. 
Results 
Follow up 
From July 1982 until October 1989, 705 infants of HBsAg positive mothers 
were randomized; 16 infants were withdrawn after informed-consent but before 
vaccination, 12 infants received at least 1 vaccination, but no serum sample was 
available after month 0. 677 infants received passive-active immunization accor-
ding to 6 schedules (table 1 ). Thirteen infants received vaccinations but not accor-
ding to protocol (1 in group I, 4 in group II, 1 in group Ill, 1 in group IV, 3 in group 
V and 3 in group VI). 664 infants received passive-active immunization according 
the protocol, 650 of 664 infants (98%) received all planned vaccinations. Serum 
samples were available from 590 children at 1 year follow-up, 546 after 2 years, 
262 after 5 years and 126 after 8 years (Table 4, appendix). Incomplete data from 
these children were primarily due to secondary refusal of the parents, related to the 
frequency of blood sampling (up to 10 samples) during the study, and migration. 
Protective efficacy of perinatal HBV immunization 
At month 12, HBsAg positivity was found in 8 of 590 infants. Of 33 infants 
no serum sample was available at month 12 but they were HBsAg negative there-
after, assuming no HBsAg positivity at month 12. From 8 out of 13 infants, who 
received a vaccination schedule not according to protocol, serum samples were 
available and found to be I-IBsAg negative at month 12 or thereafter. Together of 
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631 (590+33+8) infants analyzed, 8 (1.3%) were found to be HBsAg positive 
during the first year of life. All HBsAg positive children were born to HBeAg 
positive mothers. One infant of an HBeAg negative mother became HBsAg 
positive at the age of 5 years (figure 1). This child and all infants found to be 
HBsAg -positive in the first year, became hepatitis B carriers. 
Inapparent HBV infection (anti-HBc positivity with negative HBsAg test on 
two or more occasions after month 12), was observed in 8 infants, all of HBeAg 
positive mothers. 614 (631-9-8) infants developed anti-HBs after vaccination, 
without signs of HBV infection; in 9 children anti-HBs more than 10 IU/L deve-
loped only after revaccination. 
At month 12, Protective Efficacy Rate (PER) of passive-active immuni-
zation for the 114 infants (all immunization groups) of HBsAg and HBeAg positive 
mothers was 92% (Table 2). No significant differences were found between the 
PER of infected infants in the groups starting active vaccination at birth and groups 
starting at 3 months; between groups receiving 1 dose of HBig and groups recei-
ving 2 doses of HB!g and between groups receiving plasma- and those receiving 
recombinant vaccine (table 2). 
In 72 of the 114 HBeAg positive mothers, residual serum was available for 
quantitative HBV-DNA assessment in 1992. Table 3 shows the relation of maternal 
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Figure 1. Chronic HBV infection after 5 years of follow up in one infant, born to an !!BeAg negative 
mother, despite a weak response to neonatal passive-active hepatitis B immunization (group If). 
Analysis of serum samples of family members showed that this patient has an HBeAg positive brother. 
This might explain the horizontally transmitted HBV infection in this patient at the age of 5 years. There 
was no coexistence of HBsAg and anti-HBs positivity in the patient, full in vitro neutralization of I!BsAg 
by HB/g was observed, indicating that the HBV infection was not caused by an escape mutant. 
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HBV-DNA levels (divided in 3 groups of equal size) and number of HBV carrier 
infants. The PER at month 12 for the 2 groups with HBV-DNA levels < 150 pg/ml 
were 100% and 32% higher than that for the group with HBV-DNA levels "' 150 
pg/ml (P-value = 0.009). 
Figure 2 shows the maternal HBV-DNA levels of HBV infected infants and 
of non-infected infants. Median maternal HBV-DNA of HBV carrier infants and of 
inapparently infected infants were ten times higher (approximatively 350 pg/ml) 
than median maternal HBV-DNA of infants without HBV infection (31 pg/ml) (p= 
0.001 and 0.03, respectively). 
Table 2. t-1ficacy of passive active hepatitis B immunization, at month 12 in infants of !IBeAg positive 
mothers, according different vaccination methods 
number of infants HBsAg positivity PER 12 months a % 
difference in % 
Group total HBsAg (95% Cl) expected % of infant 
positive HBV inlections 
(%) without prophylaxis 
90% 67% 
HB!g month 0 56 4 (7.1) 0.2 (·9.2, +9.2) 92 89 
HB!g months 0,3 58 4 (6.9) 92 90 
Vaccine starting month 0 42 3 (7.1) 0.2 (-9.5, +9.9) 92 89 
Vaccine starting month 3 72 5 (6.9) 92 90 
Plasma vaccine 83 6 (7.2) 0.7 (-9.6, +110) 92 89 
Recombinant vaccine 31 2(6.5) 93 90 
Total 114 8 (7.0) 92 90 
a PER= ((expected number of HBV infections without immunoprophylaxis minus measured number of 
HBV infections in immunization group) divided by the expected number of HBV infections without 
immunoprophylaxis) x 100%. 
The expected number of HBV infections without immunoprophylaxis for infants from HBeAg positive 
mothers is usually estimated 90%. (3-5). PER was also calculated for 67 expected percentage of 1-IBV 
infections without immunoprophylaxis, in view of the finding that one third of infants of HBeAg positive 
mothers had HBV-DNA less than 5 pg/ml and therefore unlikely to transmit hepatitis B to their infants (8). 
61 
Long-term immunogenicity 
Assuming a minimal risk for hepatitis B infection with anti-HBs levels 
above 10 IU/L, and a potential risk with anti-HBs levels less than 10 IU/L (14), we 
calculated the percentages of infants with anti-HBs < 10 IU/L, in the different 
immunization groups (figure 3). At the age of 5 years, the immunization group 
starting at 3 months of age with plasma vaccine (group II) had a significantly lower 
percentage (2%, 95% CI: 0-6%) of children with anti-HBs < 10 IU/L than the 
immunization group starting at birth (group I), 14.5% (95% CI: 6-23%), (Fisher 
exact test p=0.02). The percentage of infants with anti-HBs < 10 IU/L in group II 
never exceeded 5% during 5-year follow up, whereas this corresponding percen-
tage in the other immunization groups increased during follow up to more than 15%. 
Total follow up of infants with anti-HBs less than 10 IU/L amounted to 186 
person-years: 38 from 19 of 441 infants;;, 1000 IU/L at month 12; 78 from 30 of 97 
infants with anti-HBs between 100 and 1000 IU/L; 69 from 21 of 35 infants with 
anti-HBs between 10 and 100 IU/L and 1 from 1 of 9 infants with anti-HBs less 
than 10 IU/L (the latter all developped more than 10 IU/L after revaccination). 
Six of the 8 infants with inapparent HBV infection had anti-HBs ;;, 1000 
IU/L at month 12, 2 between 10 and 100 lUlL. 
Table 4 shows the GMT of anti-HBs (anti-HBs >= 10 IU/L) in the different 
immunization groups during follow up. The GMT of anti-HBs of group II (10 1-1g 
plasma vaccine administration from 3 months of age onwards) was approxima-
tively two times higher than the GMT of anti-HBs of group I (starting at birth with 
10 1-1g plasma vaccine). In the groups with different dosages of vaccine, group Ill 
with 3 doses of 10 1-1g plasma vaccine administered from birth onwards, showed 
approximatively two times higher GMT anti-HBs at month 12 than group IV, with 
the corresponding schedule but only 5 flg of plasma vaccine. However this diffe-
rence was not significant after 36 months of follow up. Comparison of plasma- and 
recombinant- vaccine administered from 3 months onwards showed, that the group 
with plasma vaccine (group II) had an approximately one and half times higher 
GMT of anti-HBs than the corresponding group with recombinant vaccine (group 
VI) (P-value < 0.001 at all times measured). 
Side-effects 
No clinically important side-effects of vaccination were reported by the 
parents or observed by the pediatricians. 
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Table 3. Protective Efficacy Rate (PER) of passive-active hepatitis B immunization at month 12 according 
to maternal HBV-DNA levels. 
number of infants PER 12 months P-value 
HBV-DNA total HBsAg 90% 
(pg/rnl) positive (%) 
<6 24 0 (0) n.a.a 
7-150 24 0 (0) 100 
>150 24 7 (29) 68 0.009* 
* Fisher exact test between number of HBsAg positive infants in group with maternal HBV-DNA > 150 
pg/ml and the groups with HBV-DNA between 7-150 pg/ml and< 6 pg/ml, respectively. Due to small 
numbers of infants, we calculated the exact 95% CI of the ratio of the odds of 1-IBsAg positivity in the 
group of infants with HBV DNA< 150 pg/ml (odds= 0/48) versus the corresponding odds(= 7/17) in the 
group with HBV DNA> 150 pg/ml. This 95% CI ranged from 0 to 0.22. 
a n.a. is not applicable, in view of the finding that one third of infants of HBeAg positive mothers had 
HBV-DNA less than 5 pg/ml and therefore unlikely to transmit hepatitis B to their infants (8). 
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Figure 2. Maternal HBV-DNA levels of 7 persistent HBV infected infants, 4 transient HBV infected 
infants and of 61 noninfected infected infants. Cut-off level of HBV-DNA assay (HBV-DNA, Abbott, Ill, 
USA) is 1.7 pg!ml. 
Maternal HBV-DNA was not available for I HBsAg positive infant, 4 anti-HBc positive infants and 37 
noninfected infants of IlBeAg positive mothers. 
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Discussion 
In this study, the Protective Efficacy Rate at 12 months against hepatitis B 
infection for infants of HBeAg positive carrier mothers was 92%; for infants of 
HBeAg negative mothers it was 100%. These rates are comparable to those found 
in other passive-active immunization studies, with either plasma-derived or recom-
binant vaccine (1-3,15,16). During follow up beyond 1 year, extending to 9 years, 
one hepatitis B vaccinated infant of an HBeAg negative mother became positive 
forHBsAg. 
There was no effect on PER for the timing of active immunization, the 
number of doses of HB!g and the type of vaccine. Although confidence in the re-
sults is not absolute, these results are confirming to earlier findings. Beasley et a!. 
(1) already reported that, with HB!g coverage at birth, the timing of the start of ac-
tive vaccination appeared of no importance. Stevens eta!. (3) published results indi-
cating that yeast-recombinant vaccine was as effective as plasma-derived vaccine in 
preventing hepatitis B virus infection. We found no evidence for a need for a second 
dose of HB!g in combination with delayed active immunization; evidence for the 
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Figure 3. Percentages of infants with anti~HBs < 10 lUlL in the 6 immunization groups. Bars indicate 
standard errors. 
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Table 4. GMT (anti-lfBs > =10 lUlL) in the 6 immunization groups during follow up 
GMT anti-HBs (95% CI) !U/L 
months 
Groups 12 24 36 48 60 
8730 737 353 207 137 
0, 1,2,11:10 ftgpL (6238-12217) (533-1019) (248-502) (145-296) (92-203) 
II 15739 1728 820 484 331 
3, 4, 5, 11: 10 f'S pl. (11738-21104) (1234-2325) (596-1129) (356-231) (231-473) 
P-value* 0.023 0.001 0.0006 0.0004 0.0002 
III 1142 331 202 138 100 
0, 1, 6; 10 ftg pL (849-1537) (245-447) (151-271) (100-90) (70-143) 
IV 608 203 163 114 75 
0,1,6;5pgpL (438-S46) (146-283) (116-228) (7S-166) (52-109) 
p-value** 0.0012 0.0066 0.19 0.31 0.11 
v 9317 1727 
3, 4, 5, 11; 20 flg rec. (6558-13237) (1216-2452) 
VI 9699 1125 
3. 4, 5, 11; 20 !.tg rec (6475-14528) (767-1649) 
P-value*** 0.13 0.84 
* Between group I and II * * Between group III and IV * * * Between group V and VI 
Appendix 
number of serum samEles available during follow u:e {%} 
months 
groups 3 6 11 12 24 36 48 60 72 84 
102 106 99 98 92 86 85 62 73 67 
II 100 107 98 99 91 82 84 53 66 59 
III 115 119 122 107 102 84 69 
IV 114 113 112 100 98 87 78 
v 94 91 91 90 88 
VI 73 6 65 69 68 
Total 598 542 353 590 546 368 340 262 139 126 
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necessity of such action has not been forthcoming. Although some uncertainty on 
this point may persist, we found a major clinically relevant factor that influenced 
the PER. 
PER in the groups of infants with maternal HBV-DNA levels less than 150 
pg/ml was 100% and significantly higher than 68% in the group with maternal 
HBV-DNA level of more than 150 pg/ml. 
To verify the finding that the PER is markedly influenced by maternal HBV-
DNA levels, we analyzed the protective efficacy rate at 12 months of age according 
to quantified maternal HBV-DNA levels, in another large neonatal hepatitis B vac-
cination program (8) (P.N. Lelie, written communication). These results strongly 
support the concept that the level of maternal HBV-DNA is the major factor 
influencing PER of hepatitis B immunization. In the Hong Kong study, no persis-
tent HBsAg positivity at 12 months was detected in infants with maternal HEY-
DNA below 6 pg/ml, irrespective of immunization. Infants with maternal HBV-
DNA levels of more than 150 pg/ml were at high risk for hepatitis B (25-50% of 
infants became persistent HBsAg positive), despite immunization. In the Hong 
Kong study, infants with maternal HBV-DNA between 7-150 pg/ml were at risk for 
hepatitis B infection (15-28% ). 
The absence of HBsAg carriers in the group with moderately high maternal 
HBV-DNA in the Dutch study, in comparison to 15%-28% carrier rate in the Hong 
Kong study needs additional discussion. Since the rate of intrauterine infection is 
estimated to be only 1-2% (15), the difference observed is likely due to differences 
in intervention (HB!g, vaccine) or to differences in maternal fetal transfusion 
during labour. The dose of hepatitis B immunoglobulin used in the Hong Kong 
study (50 IU) was lower than that in the Dutch study (200-300 IU) and the dose of 
vaccine in the Hong Kong study (3 1-1g) was also lower than in the Dutch study (10 
1-1g). Although the dose of vaccine may not reflect immunogenicity, the GMT of 
anti-HBs in the Dutch study were almost 10 times higher than in Hong Kong, 
indicating higher immunogenicity of the vaccine used in the study in the Nether-
lands. These results also suggest that efficacy of dose of HBig and vaccine can 
now assessed more precisely in cohorts with maternal quantified HBV DNA 
levels. 
Recently, hepatitis B "escape mutants", lacking the "a" epitope on the viral 
envelope were found in vaccinated infants (17). We did not observe coexistence of 
HBsAg and anti-HBs in 7 infants with persistent HBsAg. Additional laboratory 
investigations including in vitro neutralization of HBsAg by polyclonal anti-HBs 
have provided no evidence of the presence of surface antigen variants in our 
HBsAg positive children (12). Also a clinical relevance of precore mutants was not 
found in our study, since the PER at month 12 for infants of HBeAg negative 
mothers was 100%. 
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Long-term immunogenicity was significantly higher in the group with late 
active immunization than in the group starting directly after birth. At the age of 5 
years, the group with delayed active immunization had a significantly lower 
percentage (2%, 95% CI: 0-6%) of children with anti-HBs less than 10 IU/L than 
in the groups starting at birth (15-25% ). This finding is in agreement with others 
who found an enhancement of response if the infant was older at the time of the 
initial injection, probably related to a more mature immune system (18). The 
implications of these findings are at present unclear but may become of potential 
importance if more results of long-term follow up studies become available. If 
protection against hepatitis B infection in a major way depends on the degree of 
immunologic priming reflected by persistence of antibody, then a strong argument 
could be made for adoption of schedules that maximize anti-HBs levels. In the 
present study, there was a total follow up of 186 years with anti-HBs less than 10 
IU/L in 71 infants. One infant, born to a HBeAg-negative mother, with an initial 
response between 10 and 100 IU/L became HBsAg carrier after 4 years of follow 
up without detectable anti-HBs. In other studies, no HBsAg positivity after 5 years 
of follow up was found for infants with initial anti-HBs " 10 IU/L, whether the 
infants lost their anti-HBs or not (18,19). In long-follow up studies of immunised 
adults, no persistent HBsAg positivity was detected in persons with an initial anti-
HBs response >10 SRU (14), but transient HBsAg positivity and/or anti-HBc 
positivity was detected in this group (less than 1% in 100 person-years exposed). 
For the time being, until more long-term follow up studies are available, it seems 
advisable to aim for an initial anti-HBs response of more than 10-100 !U/L for the 
prevention of clinically important forms of hepatitis B (20). 
The implications of the finding that there was no effect on PER of the 
timing of active immunization, allows incorporation of hepatitis B vaccine into the 
existing Expanded Programme on Immunization (EPI). The number of injections 
and the number of doctor visits can then be reduced if multivalent vaccine becomes 
available. The finding that maternal HBV-DNA is the most relevant clinical factor 
influencing the efficacy of standard passive-active hepatitis B immunization is 
important for improving results of intervention, in particular in countries which can 
afford high level individual care. In practice, we advocate to assess HBV-DNA 
quantatively in all HBsAg positive mothers found to be also HBeAg positive. On 
the basis of the current study we advise to offer additional preventive measures for 
infants at high risk for hepatitis B: 300 IU of HBig (1 ml instead of 0.5 ml) and 
adult dose of vaccine instead of pediatric dose to neonates of HBeAg positive 
mothers with maternal HBV-DNA level above 5 pg/ml. Further research is 
warranted to prevent hepatitis B in infants with maternal HBV DNA level above 
150 pg/ml, like evaluation of delivery by Caesarean section as proposed by Lee 
(21), or additional HB!g injections as suggested by the Hong Kong study (8). 
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Summary 
Since 1986 Health Authorities in the Netherlands recommend vaccinating 
prematurely born infants at the appropriate chronological age, without correcting 
for their shortened gestational age as the practice used to be. The advise is based on 
research indicating that the immune response after DPT (Diphteria, Pertussis, 
Tetanus) vaccination of pre term infants is comparable to the immune response of 
full term infants. To see whether this also applies to hepatitis B vaccination, we 
examined the anti-HBs titers after hepatitis B vaccination of 44 preterm infants and 
compared these to the anti-HBs titers of 829 full term infants. Over 95% of the 
preterm infants developed an adequate immune response (> 10 IU/liter) after 
primary vaccination, irrespective of the vaccination schedule. The percentage of 
children with anti-HBs titers > 10 !U/liter was not different for the group of 
pre term infants from that of the group of full term infants (98% ). Nor was it 
different when a value of > 100 IU/liter was considered. Differentiating between 
early and late active immunization we found that the percentage of children with 
anti-HBs titers > 10 IU/liter from the group vaccinated immediately after birth 
(98%) did not differ significantly from that from the group first vaccinated 3 
months after birth (99% ). There was, however, a signifficant difference between 
these two groups when a value of> 100 IU/liter was considered. This study lends 
support to the Health Authorities' advice to start vaccination of preterm infants at 
the appropriate chronological age, without correction for their shortened gesta-
tional age. 
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Introduction 
Passive and active immunization of infants born to hepatitis B virus carriers 
is an effective and safe method for the prevention of perinatal transmission of the 
hepatitis B virus. In healthy, full term newborns an adequate immune response 
(antibodies against the surface antigen (anti-HBs) > 10 international units per liter 
(IU/liter) is found after immunization with hepatitis B vaccine according to various 
immunization schedules (1,2). Apart from administration method, dosage, and 
vaccination schedule, children's immune response to hepatitis B vaccination 
probably depends on several factors, including HLA type (3), the mother's country 
of origin (4), and the occurrence of diseases influencing the immune system (5,6). 
However, so far no data were available on the immune response of preterm infants 
after hepatitis B vaccination (7). In 1986 the Health Authorities recommended 
starting the vaccination of preterm infants at the appropriate chronological age 
rather than making allowances for their shortened gestational age, as the practice 
had been (8). This advice was based on a study showing the immune response of 
25 preterm infants with a median gestation age of 31 weeks (range 28-34 weeks) to 
be similar to the immune response of full term infants after the second diphteria-
tetanus-pertussis vaccination at chronological age (9). The question is whether 
preterm infants also develop an adequate immune response after hepatitis B 
vaccination at chronological age, that is, without correcting for their shortened 
gestational age. This article describes the immune response of preterm infants at 1-
2 months after primary active-passive hepatitis B immunization (i.e. after the first 2 
or 3 successive vaccinations, depending on the schedule), which response is then 
compared with the response of full term infants. 
Patients and methods 
From 1982 till 1992, 1025 neonates were vaccinated with hepatitis B 
vaccine at three centres in the Netherlands (Twente, Utrecht, Rotterdam); 705 
children of hepatitis B surface antigen (HBsAg)-positive mothers received hepatitis 
B immunoglobulin (HB!g) at birth, followed by active immunization with plasma 
vaccine or recombinant vaccine, according to various schedules (Table 1 ). The 
vaccine was kept at a temperature of 2-6 oc and was injected in the quadriceps 
muscle. Blood sampling at birth was from the umbilical cord, and afterwards at 1, 
3, 4, 6, 11 and 12 months, depending on the schedule, and followed by annual 
sampling during a median period of 5 years (range 2 to 8 years). HBsAg and anti-
HBs levels in the serum were measured with radio-immunological tests (Ausria, 
Ausab, Abbott Laboratories, Chicago, Ill, USA). The gestational age of 46 of the 
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1025 children was less than 37 weeks (median 36.0 weeks; range 27.2 to 36.6 
weeks), the age being determined on the basis of data from their birth reports. 
Records were kept of the mother's country of origin, of the gender, weight, apgar 
score and any perinatal problems for all preterm infants. Like the full term infants, 
all 46 preterm infants were vaccinated with hepatitis B vaccine according to 
various schedules, without correction for their premature births; 23 preterm infants 
were vaccinated with hepatitis B vaccine immediately after birth (16 of those 
children also received HB!g). The other 23 preterm infants started vaccination at 3 
months (of those 13 received HB!g at birth) (Table 1 ). 
Statistics 
The immune responses of preterm infants after hepatitis B vaccination at 
their chronological age were compared with the immune responses of full term 
infants vaccinated according to corresponding schedules. Significance of percen-
tage differences between groups was determined with the use of Fisher's exact test, 
with a threshold of 0.05 (both ways). 
Results 
Forty-six children with a gestational age of less than 37 weeks were vac-
cinated with hepatitis B vaccine (4.5% of the total number of children vaccinated). 
Of those 28 were boys and 18 were girls; their median weight at birth was 2540 
grams (range 1200 to 3950 grams). For 10 preterm infants their birth weight was 
too low for their gestational age. 31 Preterm infants had an apgar score of 10 after 
5 minutes, 15 had an apgar score <10 after 5 minutes (range 6 to 9). The countries 
of origin of the mothers of the pre term infants were similar to those of the mothers 
of the full term infants. Four of the 46 preterm infants needed ventilative support 
because of a hyaline membrane disorder and 2 of these received 2 and 4 exchange 
transfusions respectively because of hyperbilirubinemia; they received no extra 
HB!g. The infant with the shortest gestational age (27. 7 weeks) suffered an 
intracranial haemorrhage and needed completely parenteral feeding for a number 
of weeks. 
Serological response 
Of the 46 pre term infants 44 received the first 2 or 3 (depending on the 
schedule) hepatitis B vaccinations and from each of these 44 infants at least one 
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Table 1. 46 preterm and 979 full term infants vaccinated with hepatitis 13 vaccine in three centers in the 
Netherlands, 1982-1992. 
group vaccination serum IIB!g 1-IBvaccine pre term fullterm 
schedule sample * ** N N 
month month 
1 0,1,2,11 0,3,6,11,12 + plasma 10 ~g 4 113 
2 3,4,5,11 0,3,6,11,12 ++ plasma IO~g 5 116 
3 0,1,6 0,3,6,12 + plasma 10l-!g 5 128 
4 0,1,6 0,3,6,12 + plasma 5l-!g 7 117 
5 3,4,5,11 0,3,4,6,11,12 + recomb. 20[.lg 4 108 
6 3,4,5,11 0,3,4,6,11,12 ++ recomb. 20~g 4 94 
7 3,4,5,11 0,4,6,11,12 recomb. 20[.lg 2 49 
8 0,1,6 0,3,6,7,12 recomb. 20~g 4 52 
9 0,1,2,11 0,3.6,11,12 recomb. 20[.lg 3 52 
10 3,4,5,11 0,4,6,11,12 recomb. 10l-!g 2 76 
11 3,4,5,11 0,4,6,11,12 recomb. S~tg 6 74 
total 46 979 
* 300 IU/ml hepatitis B immunoglobuline, (Centraal Laboratorium Bloedtransfusiedienst, Amsterdam). 
(+: HBlg month 0), ++: HBlg months 0 and 3), 
** 10 [.lg plasma vaccine and 10 ~-tg and 5 l-!g recombinant vaccine (Merck, Sharp en Dohme, Westpoint 
Pa, U.S.A.). 
20 j..lg recombinant vaccine (SmithKline Beecham. Rixensart, Belgium) 
The primary vaccinations and the month of serum sampling after these 2 vaccinations (schedule 3, 4 and 8) 
and after these 3 vaccinations (schedule L 2, 5, 6, 7, 9, 10 en 11) are in bold type. 
serum sample was available after completion of the primary vaccination series. Of 
2 preterm infants only one serum sample was known after the first vaccination; 
these children were excluded from further analysis. From 829 of the 979 full term 
infants serum samples were collected for analysis (primary vaccination was 
incomplete for 44 children and of 106 children no serum sample was available). Of 
the preterm infants 98% (43/44) had anti-HBs titers > 10 IU/liter after primary 
vaccination and 89% (39/44) had anti-HBs titers > 100 IU/ liter after primary 
vaccination. For the full term infants the percentages were 98% (816/829) and 93% 
(772/829) respectively. Neither for the limiting value of 10 U!/liter nor for for the 
limiting value of 100 !U/liter are there any significant differences between the 
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Figure 1. Titer anti-JiBs of 44 pre term infants and of 829 full term infants after hepatitis B vaccination. 
Geswtional ages of individually preterm infants(< 37.0 weeks) are shown on the horizontal axis; 
gestational ages of all full term infants(> 37.0 weeks) are shown together. (GMT= geometric mean titer: 
SD=- standard deviation) 
group of preterm infants and the group of full term infants. The percentage of 
children with anti-HBs titers > 10 IU/liter from the total group (pre- and full- term) 
of infants vaccinated at birth (98%) was not significantly different from that from 
the total group (pre- and full- term) of infants not vaccinated until month 3 (99% ). 
However, for the limiting value of 100 IU/Iiter (supposed to provide long lasting 
protection (12)) the difference between the group vaccinated at birth (90%) and the 
group vaccinated at month 3 (97%) proved significant (p < 0,001) (Table 2). Figure 
1 shows the anti-HBs levels of the preterm and full term children at month 12, after 
completion of the primary vaccination series. Of 29 preterm infants anti-HBs titers 
taken 12 months after completion of the vaccination schedule (at month 24) were 
known: 97% of the preterm infants had anti-HBs titers > 10 IU/liter and 76% had 
anti-HBs titers > 100 JU/liter. 
Nine pre term infants had a birth weight of less than 2000 grams; 6 of these 
had anti-HBs titers > 100 IU/liter after primary vaccination, 2 preterm infants with 
birthweights of 1880 and 1320 grams respectively, had anti-HBs titers between 10 
and 100 lU/liter (both had a gestational age of 32.0 weeks and were vaccinated 
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Table 2. Preterm infants and fullterm infants vaccinated with hepatitis B vaccine from birth onwards or 
from 3 months onwards; number of infants with anti-JiBs levels > 10 lUlL and > 100 lUlL 1-2 months 
after primmy vaccinations, respectively. 
start vaccination titer anti-HBs > 10 titer anti-HBs > 100 
!U/L !U/L 
from birth preterm 95% (21/22) 86% (19/22) 
onwards full term 98% (431/439) 90% (394/439) 
total 98% (452/461) 90% (413/461)* 
from 3 months pre term 100% (22/22) 95% (21/22) 
onwards fullterm 99% (385/390) 97% (378/390) 
total 99% (407/412) 97% (399/412)* 
*Fisher's exact test: p < 0.001 
according to schedules 10 and 11 respectively). One infant, born pre- and dysma-
turely (gestational age 35.0 weeks, birth weight 1955 grams), had an anti-HBs titer 
< 10 IU/liter after primary vaccination according to schedule 4. Of the 35 preterm 
infants with birth weights " 2000 grams no child had an anti-HBs titer less than 10 
IU/liter after completion of the vaccinations and 2 children had anti-HBs titers 
between 10 and 100 IU/liter. There was no significant difference in this respect 
between the group of preterm infants < 2000 grams and the group of preterm 
infants " 2000 grams. 
Four preterm infants had passively acquired anti-HBs (anti-HBs titers from 
umbilical cord blood ranging from 250 to 16250 IU/liter). With 3 of those infants 
the level of anti-HBs rose after primary vaccination and with one infant the level 
fell from 16250 to 1400 IU /liter after primary vaccination according to schedule 
11. The 4 preterm infants with titers between 10 and 100 IU/liter were all vac-
cinated according to different schedules (schedules 1, 8, 10 and 11 respectively). 
The one infant born pre- and dysmaturely (35.0 weeks, 1955 grams, several 
weeks of artificial respiration) whose response after primary vaccination was 
severely inadequate (anti-HBs titer 2 !U/liter) received a complete new series of 
vaccinations during its second year and then developed a response of over 3000 
!U/liter anti-HBs. Eight full term low-responders (titers anti-HBs ,; 10 IU/liter) 
similarly developed an adequate immune response after revaccination in the course of 
their second year. One of the 44 preterm infants eventually became an hepatitis B 
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carrier (HBsAg-positive) at the age of 5. Its anti-HBs titer after primary vaccination 
according to schedule 2 was 45 IV /liter, at month 12 (after the booster vaccination) it 
was only 6 IU/liter. Of the 827 full term infants 8 became HBsAg-positive. 
The anti-HBs titers at month 3 of 2 preterm infants (gestational age 33.0 and 
27.0 weeks, vaccinated according to schedules 2 and 3 respectively) who had 
received several exchange transfusions, were only 20 and 16 IU/liter respectively. 
In both cases the deviation from the geometric mean titer (GMT) is more than 
twice the standard deviation (SO) (GMTs for schedules 2 and 3 are 34 and 42 
IU/liter respectively). At month 12 both children had anti-HBs titers> 100 !U/liter. 
ln neither group (preterm and full term infants) any serious side effects of 
the hepatitis B vaccine were reported. 
Discussion 
This study shows that 97% of preterm infants vaccinated with hepatitis B 
vaccine at chronolological age can develop an adequate immune response to 
hepatitis B without notable side effects. This percentage is similiar to that of full 
term infants with an adequate immune response after hepatitis B vaccination (1,2). 
The percentage of preterm infants with anti-HBs titers remaining > 10 IU/liter 
during their second year, was 97, which is even higher than the percentage found in 
the literature (94%) (12). 
The immune response to hepatitis B vaccinatie depends from genetic as well 
as environmental factors (3-6). No serious diseases weakening the immune system 
were known to occur with either the preterm or the full term infants. No HLA-
typing was done for either group, since there is no reason to assume the HLA-type 
corresponding with low immune responses to be specific for preterm infants. Anti-
HBs titers taken after vaccination from children with passively acquired anti-HBs 
are difficult to interpret. Previous results, however, give no reason to suppose anti-
HBs of maternal origin to impede an effective immune response (even after very 
low doses hepatitis B vaccine) (13). This assumption is supported by the rise, after 
primary vaccination, of the anti-HBs titers of 3 of the 4 preterm infants with 
positive anti-HBs. 
Some people suggest that children weighing less than 2000 grams at birth 
react less well to hepatitis B vaccination than children with normal birth weight, 
and advise to postpone vaccination until normal weight it reached (14). In our 
study we found no significant difference in adequate immune response between 
infants < 2000 grams and infants "' 2000 grams. We therefore see no reason to 
postpone hepatitis B vaccination on the grounds of a too low birth weight. The 
ability to develop antibodies increases with age; however, Dancis et al. supposed 
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early exposition to antigens to be more important to the formation of antibodies 
than the stage of maturation of the immune system (15). Our study too showed 
preterm infants vaccinated at chronological age to be able at an early age to build 
an adequate immune response after hepatitis B vaccination. However, comparison 
of anti-HBs GMTs of both groups is difficult because of the extent of the range of 
anti-HBs titers of both preterm and full term infants in the various vaccination 
schedules (Figure 1), and also because of the relatively small number of preterm 
infants per vaccination schedule. What does appear to effect the anti-HBs titers is 
the starting point of the active immunization, irrespective of the gestational age. A 
starting point for active hepatitis B immunization at month 3 tends to lead to higher 
anti-HBs titers than a starting point at birth, which points to the importance of a 
longer exposition to antigens before the formation of antibodies. 
The vaccination schedule as adopted in the Netherlands, which administers 
HB!g (CLB, 300 IU) to children born to hepatitis B surface antigen-positive 
mothers at birth and starts active immunization at month 3, must be considered 
superior to schedules starting vaccination at birth (16). The schedule is synchronic 
with the DTPP ( diphteria, pertussis, tetanus, polio) vaccination schedule, which 
greatly enhances the practicability (7). Recently it has become known that pre term 
infants can develop an immune response to DTPP comparable with that of full term 
infants, although few data are available for very young ( < 28 weeks) pre term infants (9-
11 ). Our study too included only one infant with a gestational age of less than 28 weeks. 
Our study included 2 children who received several exchange transfusions. 
Both children had relatively low anti-HBs titers from month 3 onwards. The HB!g 
administered passively at birth bridges the gap between birth and month 3, the 
starting point for active immunization. With an exchange transfusion the plasma of 
a child of an HBsAg-positive mother is replaced shortly after HB!g is adminis-
tered, which might theoretically lead to inadequate protection (anti-HBs titer < 10 
IU/liter) against hepatitis B, if active immunization has not yet started. This leads 
to an increased risk of hepatitis B infection. Administration of additional doses of 
HB!g to infants (both preterm and full term) receiving exchange transfusions might 
prevent this increase. High risk of infection through the mother (vertical trans-
mission) makes such prevention particularly desirable. Indications of the risk of 
vertical transmission include signs of active viral replication (mother HBeAg- and 
HEY-DNA-positive as well as HBsAg-positive). Investigations into the effects of 
exchange transfusions on passively acquired anti-HBs titers would give us more 
insight into this hypothesis. 
This study so far supports the recommendation of the Health Authorities to 
start hepatitis B vaccination of preterm infants at the appropriate chronological age, 
without correcting for their gestational age. 
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Introduction 
Passive-active immunization with hepatitis B immunoglobuline and hepa-
titis B vaccine has proved to be highly effective in preventing perinatal trans-
mission of hepatitis B infection (1-2). An anti-HBs antibody level> 10 IU/1 is con-
sidered to provide protection against hepatitis B infection (3). Response to the 
vaccine depends on host factors like age, HLA type ( 4) and the presence of 
diseases affecting immunity (5-6). The immune response (expressed in IU/1) is 
higher in neonates than in adults (7). Still, inadequate responses to hepatitis B 
vaccine do occur. In adults additional vaccination in non- and low-responders has 
been reported to yield responses in 27-100% (8-10). The question: how to manage 
nonresponders, also arises for young children. As far as we know no data are 
available on additional vaccination in infants. Therefore, we report the results of 
revaccination offered to 9 healthy neonates who developed less or equal than 10 
IU/1 anti-HBs after primovaccination and a booster dose. 
Methods 
During the past 9 years 705 healthy newborns from HBsAg positive mothers 
received HB!g (120-300 IU, CLB, Amsterdam, The Netherlands) at birth and were 
vaccinated within the first year with plasma or recombinant-DNA vaccine according 
to several schemes including at least 2 initial doses and a booster dose. 
Vaccine was always stored at 4 oc and given into the quadriceps muscle by 
physicians. HBsAg and anti-HBs were measured (Ausria II, Ausab, Abbott 
Laboratories) one month after completion of the immunization schedule. Nine 
infants with a negative test for HBsAg and an anti-HBs level,; 10 IU/1 received 3-4 
additional doses of plasma-derived (10 1-1g) or recombinant-DNA (20 1-1g) vaccine 
in their second year of life. 
Results 
Mter revaccination all infants showed an anti-HBs response above 10 IU/1; 
7 children (78%) developed >50 IU/1 anti-HBs and four of them more than 100 
IU/1. The three non-responders after primovaccination (anti-HBs 0 !U/L) had a 
response in the lower range (figure 1 ). No hepatitis B infections were observed 
among these nine children during follow-up (median 51, range 33-92 months). 
Twelve months after completion of revaccination 8 of the 9 infants (89%) still had 
more than 10 IU/1 anti-HBs. 
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Figure l.Anti-HBs response after hepatitis B revaccination in infants, who were low-responder (n=6) or 
non-responder (n=3) after primo vaccination and a booster dose. The non-responders are indicated by 
arrows. 
Discussion 
Our data show that additional vaccination of infants, who had a non-detec-
table or a weak response after primovaccination and no signs of hepatitis B infec-
tion, can yield responses with a high likelihood of protection against hepatitis B 
infection. From an epidemiological viewpoint this result is important since many of 
these children remain at risk for hepatitis B infection for years due to family 
contacts. 
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Introduction 
Immunization with hepatitis B vaccine has proven to be highly effective in 
preventing transmission of hepatitis B infection (1-2). Nevertheless, inadequate 
responses to hepatitis B vaccine occur and vaccine recipients may therefore remain 
susceptible to hepatitis B virus infection. Factors that influence the response to 
vaccination include age (3) and the immunogenetic state of the vaccine recipient; 
the frequency of Human Leucocyte Antigens (HLA)-DR3 was increased in those 
who did not develop an adequate response to hepatitis B vaccination (4). Age 
appears to be an important factor in the mechanism of non/low responsiveness in 
adults (rate approximately 25%) but not in neonates (non/low response rate less 
than 10%) (5). To determine the importance of the immunogenetic factor for the 
outcome of hepatitis B vaccination in neonates, we investigated the HLA type of 
infants with an inadequate response to hepatitis B vaccination. 
Methods 
Between 1982 and 1991, 705 healthy newborns from HBsAg-positive 
mothers received HBig (150-300 IU, CLB, Amsterdam, The Netherlands) at birth 
and were vaccinated within the first year with plasma or recombinant-DNA 
vaccine* according to a three or four-dose vaccination schedule. Anti-HBs and 
HBsAg were measured at 3, 6, 11 and 12 months of age. Infants who did not 
respond adequately to the vaccination (anti-HBs < 10 IU/L at month 12) and were 
still HBsAg-negative were revaccinated in their second year of life. Sixteen of the 
705 newborns (2.3 %) had anti-HBs titres < 10 IU/L. In December 1991, 8 infants 
(7 Caucasians and 1 from Cape Verde Islands) with an anti-HBs level below 10 
IU/L and a negative test for HBsAg (noninfected low responders) and another 8 
infants (6 Caucasians, 2 Asians) who were anti-HBs negative but 1-IBsAg- positive 
(infected nonresponders) were identified. 
HLA typing for class I and II antigens was performed, using microcyto-
toxity test on peripheral blood mononuclear cells (Tissue Typing Laboratory, head: 
Dr. G.M.Th. Schreuder, Department of Immunohaematology and Blood bank, 
University Hospital, Leiden, The Netherlands). Anti-HBs and HBsAg levels were 
assessed with commercial radioimmunoassays (Ausria II, Ausab, Abbott Labo-
ratories Chicago, ILL, USA). 
* 10 1-tg plasma vaccine and 5 1-tg and 10 f..lg recombinant vaccine (Merck, Sharp and Dohme, Westpoint 
Pa, United States of America). 20 [.tg recombinant vaccine (SmithKline Biologicals, Rixensart, Belgium). 
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Results 
Table 1 shows the HLA phenotypes of the 8 noninfected low responders and 
the 8 infected nonresponders to hepatitis B vaccine. HLA-DR3 was present in 4 of 
the 8 (50%) noninfected low responders and none of the 8 (0%) infected nonres-
ponders. Two noninfected low responders (numbers 1 and 2) were probably 
homozygous for HLA-DR3. None of the infants were homozygous for the HLA-
B8-DR3 haplotype. A rough estimate of expected DR3 homozygotes in this ethnic 
group is 1-2%. 
Discussion 
This study suggests that the HLA-DR3 haplotype plays a role in the low 
responsiveness to hepatitis B vaccination in noninfected neonates. Response to the 
vaccine depends on host factors such as age (3), the presence of diseases affecting 
immunity (6-9) and HLA type (4,10-15). There is evidence that Caucasian 
individuals homozygous for HLA-B8,SCOl,DR3 lack an immune response gene 
for HBsAg and produce much lower levels of antibody against hepatitis B vaccine 
than individuals heterozygous for or lacking this haplotype (10, 15). Moreover the 
frequency of HLA-DR3 (30%) was significantly increased in individuals who did 
not develop an adequate response to hepatitis B vaccination in the absence of 
HBsAg (noninfected lowresponders) (4,13). In our study with only a small number 
of ethnically heterozygous individuals, it is striking that all 4 DR3 positive children 
were in the group of noninfected low responders and that two of them were 
probably homozygous for DR3. These low responders were not absolute low 
responders, since all of them developed protective anti-HBs levels after hepatitis B 
revaccination in their second year of life, as described recently (16). The 2 children 
homozygous for HLA-DR3 produced anti-HBs in the lower range (45 en 55 IU/L) 
after revaccination in comparison to the other 6 revaccinated low responders 
(median 171, range 49-3497 IU/L), which is consistent with the hypothesis of a 
recessive-DR3 associated low responsiveness to hepatitis B vaccine (10,15). The 
observation that none of the 8 nonresponders, who became infected with hepatitis 
B virus, was DR3 positive suggests that HLA-associated low responsiveness is not 
causally related to this type of failure of hepatitis B vaccination. 
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Table 1. liLA type for 8 noninfected low responders and 8 infected nonresponders to hepatitis B vaccine. 
group HLA type 
noninfected 
low responders ethnics* A B c DR DQ 
1 Medit. 2 3 7 8 7 3 2 
2 Neth. 3 30 62 18 3 5 3 2 
3 Medit. 3 30 13 35 4 6 1 3 2 5 
4 Neth. 1 11 8 56 1 7 1 3 2 5 
5 Medit. 26 11 18 35 4 7 4 7 8 
6 Medit. 2 11 35 53 4 4 11 7 8 
7 Cap. V. 2 23 58 2 13 11 6 7 
8 Medit. 3 28 60 72 10 13 15 6 
infected 
nonresponders 
1** Medit. 11 28 18 48 7 4 14 5 7 
2** Medit. 11 28 18 48 7 4 14 5 7 
3 Medit. 2 24 49 35 4 7 2 
4 Medit. 3 35 37 4 11 7 
5 Medit. 3 24 35 4 11 8 7 4 
6 Asia 3 33 58 10 15 13 6 1 
7 Medit. 1 33 52 63 10 4 15 7 6 2 
8 Asia 24 11 55 61 1 10 11 13 6 7 
* Ethnic background: Mediterranean, the Netherlands, Cape Verde Islands, Asia. 
**Infected nonresponders 1 and 2 are brother and sister. 
- Possible homozygous 
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Abstract 
In a hepatitis B vaccination programme (1982-1992), 705 infants from 
HBsAg- positive mothers received HB!g within 2 hours of birth and were vac-
cinated according to a three- or four-dose vaccination schedule starting either at 
month 3 or directly after birth. Eight children became HBsAg-positive during the 
first year of life (group 1: infected nonresponders ). In order to determine whether 
failure of the hepatitis B vaccination was due to perinatal maternal high-level 
viraemia or genetically determined infant nonresponsiveness to the vaccine, we 
measured HBsAg and anti-HBs levels in infants and HBeAg and HBV-DNA levels 
in maternal serum and determined the HLA type of the infants. Controls included 
14 infants with a normal anti-HBs response 1 year after vaccination (group 2: non-
infected responders) and all 8 infants without HBsAg and antiHBs 1 year after 
vaccination (group 3: noninfected low responders). 
HBsAg, HBeAg and anti-HBs were measured by radioimmunoassay 
(Abbott Laboratories), HBV-DNA quantitatively by solution hybridization for 
groups 1, 2 and 3 (Abbott HBV-DNA assay, Abbott Laboratories); HLA was 
characterized by microcytotoxicity test for groups 1 and 3. 
All infants in groups 1 and 2 were born of HBeAg carrier mothers, those in 
group 3 of HBeAg-negative mothers. HBV-DNA levels in maternal serum in group 
1 were significantly higher than in group 2 (Wilcoxon rank-sum test: p < 0.01). 
HBV-DNA was not observed in group 3 maternal serum samples. HLA B8 and 
DR3 were not found in group 1 but were present in 4/8 and 2/8 infants of group 3, 
respectively. 
Failure of current passive-active hepatitis B immunization appears to be 
related not to genetic nonresponsiveness of infants but rather to perinatal maternal 
high-level viraemia. HBV-DNA assay of HBeAg-positive mothers may identify 
those infants in need of additional action to lower the risk of vertically transmitted 
HBV infection. 
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Introduction 
Passive-active immunization with hepatitis B immune globulin (HB!g) and 
hepatitis B vaccine has proved to be highly effective in preventing perinatal trans-
mission of hepatitis B virus (HBV) infection (1-2). Nevertheless, inadequate res-
ponses to hepatitis B vaccine occur; 1-2 % of properly vaccinated infants of 
HBsAg-positive carrier mothers become HBsAg-positive and another 1-2% of the 
infants are not able to develop sufficient amounts of anti-HBs for longlasting 
immunity against HBV. An inadequate response is defined as an anti-HBs titre of 
less than 10 IU/L after completion of the immunization schedule in infants with 
HBsAg or without HBsAg positivity. Failure of immunoprophylaxis could be due 
to either in utero infection (3); a high dose of HBV, transmitted during delivery and 
related to maternal high-level viraemia ( 4-7); insufficient neutralization capacity of 
the HB!g injection; or failure to respond adequately to the vaccine, given in an 
adequate dose, due to genetic (8-11) or acquired causes (12-15). We analysed some 
of the possible causes of hepatitis B prophylaxis failure in neonates of HBsAg 
carrier mothers in order to determine the need for modified action for those babies 
at high risk for vertically transmitted HBV infection. 
Methods 
Between 1982 and 1991, 705 healthy newborns of HBsAg-positive mothers 
received 0.5 ml HB!g/kg bodyweight (100 IU anti-HBs/ml, CLB, Amsterdam, The 
Netherlands) at birth and were vaccinated within the first year with plasma or 
recombinant-DNA vaccine* according to a three- or four-dose vaccination sche-
dule (16). 
Eight children became HBsAg-positive during the first year of life (group 1: . 
infected nonresponders ). In order to determine whether the causes of the failure of 
hepatitis B vaccination were due to perinatal maternal high-level viraemia in 
combination with pregnancy-associated maternal-foetal transfusion or genetically 
determined infant nonresponsiveness to the vaccine, we measured HBsAg and anti-
HBs levels in infants and HBeAg and HBV-DNA levels in maternal serum taken 
during pregnancy or just before delivery and determined the HLA type of the infants. 
As controls, we included 14 HBsAg-negative infants with a normal anti-HBs (> 100 
*10 ~g plasma vaccine and 5 f.-lg and 10 !J.g recombinant vaccine (Merck, Sharp and Dohme, Westpoint 
Pa, United States of America). 20 !Jog recombinant vaccine (SmithKJine Biologicals, Rixensart, Belgium). 
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Table 1. Anti-HBs level and onset of HBsAg-positivity in 8 infected nonresponders (group I) to hepatitis B 
vaccine. 
anti-HBs (IU/L) HBsAg 
infected 
nonresponders 3 6 11 12 months 3 6 11 12 
1 0 0 0 0 + + + + 
2 0 0 0 0 + + + + 
3 0 3 5 2st + + + + 
4 16 2 0 0 + + + 
5 29 0 0 6t + + + 
6 58 0 * 0 * + + 
7 38 17 0 0 + + 
8 45 39 0 0 + + 
*no test result available 
t heterotypical anti-HBs 
Table 2. HIA-B8-DR3 type in 16 non/low responders to hepatitis B vaccine. 
HLA type 
B8+DR3- B8-DR3+ B8+DR3+ B8-DR-
total 
infected nonresponders 8 0 0 0 8 
noninfected low responders 8 0 2' 2* 4 
*1 was homozygous for DR3 antigen 
Risk factors for maternal-foetal transfusion 
Risk factors for pregnancy-associated maternal-foetal transfusion, including 
threatened abortion, amniocentesis, chorion villus sampling and assisted delivery 
(vacuum, forceps), were not present. 
IU/L) response to vaccination (group 2: noninfected responders) and all 8 HBsAg-
negative infants with an anti-HBs level of less than 10 !U/L one month after 
completion of the immunization schedule (group 3: noninfected low responders). 
The fourteen noninfected responders, chosen at random, were matched with the 
infected nonresponders for maternal HBeAg and the vaccination schedule used. 
HBsAg, HBeAg and anti-HBs were assessed using commercial radioim-
munoassays (Abbott Laboratories,Chicago, Ill, USA). HBV-DNA was quantitated 
by solution hybridization for groups 1, 2 and 3 (HBV-DNA assay, Abbott Labora-
tories, USA). HLA typing for class I and II antigens was performed for groups 1 
and 3 using a microcytotoxicity test on peripheral blood mononuclear cells (Tissue 
Typing Laboratory, Department of Immunohaematology and Blood bank, Univer-
sity Hospital, Leiden, The Netherlands). 
In order to exclude HBV variants, escaping anti-HBs control, serum sam-
ples of HBsAg infants, taken between 1 and 7 year of age, were diluted to about 3 
ng/ml and incubated for 2 hours at room temperature with various amounts of 
HB!g (1-4094 !U/L). Residual HBsAg was measured thereafter in the HBsAg 
assay (neutralization in solution assay). Full neutralization is defined as reduction 
of HBsAg to the level of the negative control sample in the HBsAg assay. 
Statistical comparison of HBV-DNA levels was performed by means of the 
Wilcoxon rank -sum test. 
Results 
Onset of HBsAg-positivity and anti-HBs levels in group 1 (table 1) 
Three infants of group 1 were HBsAg-positive from 3 months of age on-
wards without detectable anti-HBs. In one of these 3 children, presumably vaccine-
induced heterotypical anti-HBs increased slowly during the first year of follow up. 
Five infants developed HBsAg between 3-11 months after birth. Low anti-HBs 
levels ( < 50 IU/L), probably still derived from HB!g, were measured in the 
preceding months. 
HBsAg neutralization in group 1 
In an in vitro assay, full neutralization of HBsAg of HBsAg-positive infants 
was obtained in all cases with 1000-4000 IU/L HBig (neutralization in solution 
assay), indicating that the HBV infection in the infants is not the result of mismat-
ching between HBig and variant HBsAg. 
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Figure 1. HBV-DNA levels in HBeAg-positive mothers of 7 infected nonresponders* (median 314, range 
152-567 pg!ml) and 14 noninfected responders (median 4.5, range 0-618 pg/ml) and in 8 HBeAg-negative 
mothers of noninfected responders to hepatitis B vaccine (all negative). 
*maternal HBV-DNA of 1 infected nonresponder is not available 
Maternal level viraemia 
HBeAg 
118/705 (16.7%) HBsAg positive mothers were also positive for HBeAg. 
All 8 infected nonresponders (group 1) and 14 noninfected responders (group 2) 
were born of HBeAg carrier mothers. Eight noninfected low responders (group 3) 
were born of HBeAg-negative mothers. 
HBV-DNA 
Figure 1 shows the HBV-DNA levels in maternal serum for group 1, group 
2 and group 3. The HBV-DNA level in maternal serum was significantly higher in 
group 1 than in group 2 (Wilcoxon rank-sum test, p < 0.01). All 8 maternal HBV-
DNA assays in group 3 (HBeAg negative mothers) were negative. 
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HLA type in infants 
HLA-B8-DR3 was not found in any infants in group 1 whereas 4 infants in 
group 3 were HLA-DR3 positive and of which 2 were also HLA-B8 positive. Table 
2 shows the HLA characteristics of groups 1 and 3. Two noninfected low respon-
ders were probably homozygous for HLA-DR3 (a rough estimate of expected DR3 
homozygotes in this ethnic group is 1-2%). 
Discussion 
The present study shows that in this series failure of hepatitis B vaccination 
was most likely due to high perinatal levels of HBV-DNA in the HBeAg carrier 
mothers. We found no evidence for genetically determined nonresponsiveness to 
the vaccine in HBV-infected children. It is believed that intra-uterine HBV 
infection occurs in 1-2% (3/235) of infants of HBeAg positive HBV carrier 
mothers (3). For a similar incidence (1-2%) in our study, intra-uterine infections 
can be expected in 2/118 infants of HBeAg carrier mothers. Eight HBsAg positive 
infants were detected in our study, that means that there are remaining causes of 
failure of hepatitis B vaccination. The HBV-DNA levels in HBsAg, HBeAg carrier 
mothers whose babies became infected were significantly higher than those in 
corresponding mothers whose babies were protected by passive and active 
immunization, which is consistent with previously published results ( 4-7). These 
HBV-DNA levels were much higher than the risk level of 5 pg/ml, reported by Ip 
and colleagues (5). We also found a lower frequency of the HBV carrier state for 
infants (6.8% (8/118) of infants at risk for HBV). Ip et al. detected 12.7% (14/110) 
HBsAg positive infants from infants at risk for HBV, despite passive-active 
hepatitis B immunization (5). An explanation may be the higher doses of both 
HB!g and vaccine used in our study. The amount of HB!g was probably not even 
high enough in these infants, because anti-HBs levels dropped down after 3 months 
of age or even earlier and HBsAg became or remained positive. Until now we did 
not observe a-deficient HBV mutants in The Netherlands, as seen in Italy (17). The 
fact that we did not see a coexistence between HBsAg and anti-HBs in 7 infants 
and that full neutralization of HBsAg was obtained by HB!g in all 8 infants 
assumes no surface antigen variants in our study population. Apart from in utero 
infection, HBV infection in infants born to HBeAg carriers with high serum levels 
of HBV-DNA can possibly be avoided by additional doses of HB!g given at birth -
to increase the capacity to neutralize HBV - followed by active immunization, or 
by caesarean section - to reduce the amount of HBV acquired by maternal-foetal 
transfusion- together with passive and active immunization at birth (18,19). 
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Assaying HBV-DNA of HBeAg positive mothers (in areas with a low incidence of 
the precore mutant), may identify those infants in need of additional action to 
lower the risk of vertically transmitted HBV infection. 
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Abstract 
Objective: To describe virological, clinical and biochemical characteristics of 
infants who became hepatitis B infected in spite of passive-active hepatitis 
B immunisation. 
Patients: As part of the research programme of the study group "Prevention 
Neonatal Hepatitis B", 705 newborns of HBsAg positive mothers received 
hepatitis B immunoglobulines directly after birth, in the period 1982-1989. 
Active immunization with plasma vaccine or recombinant-DNA vaccine 
occurred in the first year of life according a three-dose or a four-dose 
schedule. Despite passive-active immunization, 9 children became positive 
forHBsAg. 
Results: Median follow up was 5 years (range 3-8 years). Eight of the 9 infants 
were also positive for HBeAg. At the end of the follow up 1 child lost 
HBsAg and 2 children lost HBeAg. Only 1 child experienced a symptoma-
tic hepatitis B infection with raised transaminase levels. The other 8 infants 
with chronic hepatitis B were not symptomatic and were in excellent health. 
Transaminase levels were ever normal in 7 infants. 
Conclusion: Most of the infants who became HBsAg positive, in spite of passive-
active hepatitis B immunisation, developed a chronic hepatitis B infection, 
without clinical and biochemical dysfunctions. On the basis of these 
findings and recent literature concerning possible therapy, guidelines are 
given for the follow up of children with chronic hepatitis B. 
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Introduction 
The principal objective of hepatitis B vaccination programmes is the pre-
vention of chronic hepatitis, cirrhosis, and hepato-cellular carcinoma. Passive-
active immunization with hepatitis B immunoglobulin (HB!g) and hepatitis B 
vaccine has proven very effective (85-97%) in the prevention of perinatal trans-
mission of hepatitis B infection (1-3). 
This kind of infection chiefly occurs around the time of birth and without 
immuno-prophylaxis it leads to, usually prolonged (5), chronic hepatitis B carrier-
ship in 70-90% ( 4). In a Taiwanese study (5) only 9 out of 370 children (2/244 
HBsAg-positive mothers, 7/126 HBsAg-negative mothers) lost HBsAg within 4.3 
years (HBsAg loss < 1% per year). The incidence of the transition from active 
replication of the virus to virus latency (HBeAg sera-conversion) is also low: < 2% 
per year (6). 
This article describes the virological, clinical, and biochemical aspects of the 
course of the hepatitis B infection of 9 children of HBsAg-positive mothers, who 
became hepatitis B carriers in spite of passive-active vaccination. These findings are 
compared with data from the literature on hepatitis B-positive children who were 
not vaccinated. On the basis of our findings and of recent literature on possible 
therapies, we offer guidelines for the treatment of young HBsAg-positve children. 
Patients and methods 
In the scope of a study by the "Prevention Neonatal Hepatitis B" group 705 
neonates born to HBsAg-positive mothers (country of origin: The Netherlands 
n=83, Mediterranean n=74, Surinam n=74, Asia n=102, other n=69) received HBig 
(150-300 IU, CLB, Amsterdam) at birth, during the period 1982-1889. Active 
vaccination with 10 ~g plasma vaccine and 5 ~g and 10 ~g recombinant vaccine 
(Merck, Sharp and Dohme, Westpoint, USA) and 20 ~g recombinant vaccine 
(SmithKline Beecham Biologicals, Rixensart, Belgium) was executed according to 
a 3-dose or a 4-dose schedule (7). 
Blood sampling took place at birth and at months 3, 6, 11, and 12; thereafter 
annually during a median period of 5 years (range 2 to 8 years). All blood samples 
from the first year of life were tested for anti-HBs, anti-HBc, and HBsAg. HBsAg-
negative children were subsequently tested annually for anti-HBs and anti-HBc. 
Anamnesis, physical examination, HBsAg, anti-HBs, HBeAg and anti-HBc 
tests of the HBsAg-positive children were, if possible, carried out annually, and in 
addition their hepatic functions (ASAT, ALAT, Alk. phosphatase, alpha-feto-
protein) were tested and an occasional echo abdomen was made. Serum was tested 
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once for antibodies against hepatitis delta (anti-HD), during the year that HBsAg-
positivity was diagnosed. 
The mother's blood was tested for HBeAg during pregnancy of just before 
delivery, and when found positive it was also tested for HBV-DNA. 
HBsAg, anti-HBs, HBeAg, and anti-HBc were analyzed in the serum by 
means of radio-immuno-tests. Anti-HD was determined by an enzym-immuno-test. 
HBV-DNA was determined quantitively by means of a fluid hybridisation method 
(Abbott Laboratories, Chicago, Ill, USA). 
Statistics 
Clearance rates of HBsAg and HBeAg were computed by dividing the number 
of children that had become negative for HBsAg and HBeAg respectively, by the 
number of years of HBsAg-positivity observation and HBeAg-positivity observation 
respectively. 95% Confidence Intervals were computed for the clearance rates (8). 
Results 
Nine from the 705 children (6 boys and 3 girls) from our vaccination 
program became HBsAg positive. These 9 children were observed for a period of 3 
to 8 years (median= 5 years). 
Virology children 
HBsAg 
Onset of detection: 8 children became HBsAg-positive during their first 
year of life and 1 child at age 5. Of the 8 children 3 were already HBsAg-positive 
at month 3, the other 5 children became HBsAg-positive between month 3 and 
month 11 (Figure 1). The child that became HBsAg-positive at age 5 may have 
become infected through an HBeAg-positive brother. 
Clearance rate: at the end of the follow-up 1 child had lost HBsAg at year 2 
(nr. 6). Total clearance rate of HBsAg was 3% (95% CI: 0.4-22%) per year. 
HBeAg 
Onset of detection: 8 of the 9 children when found HBsAg-positive were 
HBeAg-positive as well; 1 child was HBeAg-negative (Figure 1). 
Clearance rate: at the end of the follow-up 2 of these 8 HBeAg-positive 
children had become negative at year 2 and year 3 respectively. Total clearance rate 
of the 8 HBeAg- and HBsAg-positive children was 7% (95% CI: 3-19%) per year. 
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10 Figure 1. Chronic hepatitis /3 infection in 
9 infants despite hepatitis B vaccination. 
Table 1. Anti-JiBs level and onset of llBsAg positivity in eight infams who became HBsAg carrier despite 
passive-active immunisation in their first year of life. 
anti-HBs (IU/L) HBsAg 
hepatitis B 
earners 3 6 11 12 months 3 6 11 12 
1* 0 0 0 0 + + + + 
2* 0 0 0 0 + + + + 
3* 0 3 5 281" + + + +tt 
4 16 2 0 0 + + + 
5 45 39 0 0 + + 
6 29 0 0 6t + + +tt 
7 38 17 0 0 + + 
8 58 0 ** 0 ** + + 
* intrauterine infection 
* * no test result available 
t heterotypical anti-HBs 
tt no signs for mutant-virus 
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Anti-HBs 
In 2 of the 3 children that were HBsAg-positive from month 3 onwards, 
anti-HBs was never found in 2 children; 1 child developed anti-HBs, heterotypical 
with respect to the circulating HBsAg (Table 1 ). In the remaining 5 children that 
became HBsAg positive during their first year of life, anti-HBs of 16-58 IU/liter 
originating from hepatitis B immunoglobulin (HB!g) was found at month 3. After 
month 6 no anti-HBs or only heterotypical anti-HBs was detectable (Table 1). The 
HBsAg-positive child that lost HBsAg again in year 2 (nr. 6) developed anti-HBs 
from its second year, with titers varying from 10 to 50 IU/liter during 5 years of 
follow-up. The child that became HBsAg-positive at year 5 (Figure 1, nr. 9) 
showed a weak immune response after vaccination: anti-HBs titer of 43 IU/liter at 
month 12, 0 IU/liter at months 24-48. 
Anti-HBc 
Seven of the 9 children had anti-HBc from birth. Two children from 1 
family were anti-HBc-negative until month 12; one of these developed anti-HBc 
between months 12 and 24, the other remains anti-HBc-negative until today 
(observation period 5 years). There is no reason to suppose a general immune 
dysfunction: both children are in excellent health and produce IgG-antibodies 
against Rubella and Measles vaccine. There are no indications for a mutated 
hepatitis B virus in these children (sequential analysis HBV-DNA, H. Will, 
Heinrich Fette Institut fiir Experimentele Virologie und Immunologie, Universitiit 
Hamburg, Germany; personal communication). 
Anti-HD 
Antibodies against hepatitis delta was found in none of the HBsAg-positve 
children during the first year after HBsAg-positivity was detected. 
Virology mothers 
HBeAg of 8 of the 9 mothers was positive. The child that became HBsAg-
positive at year 5 had a HBeAg-negative mother. HBV-DNA of 7 HBeAg-positive 
mothers was median 314 pg/ml, range 152-567 pg/ml. 
Clinical and biochemical data 
Summer 1992, all children are in good health and attend primary school. 
One child (nr. 4) suffered a symptomatic hepatitis B infection at month 7: insuffi-
cient feeding and groaning were reason for hospitalization. There was no icterus; 
serum transaminases were raised, ASAT 80-150 IU/liter, ALAT 200-300 IU/liter 
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(normal for neonates less than 80 IU/liter). Ultra-sound scanning showed an 
enlarged liver and speen, compatible with a diffuse process in the liver. Within a 
few months hepatic functions returned to normal, but HBsAg remained positive. 
The remaining 8 children were asymptomatic at the time of detection of HBsAg-
positivity and showed no signs of hepatomegaly, splenomegaly, spider naevi or 
other characteristics of chronic hepatic disease. Serum transaminases, alpha-
fetoprotein and ultra-sound scans of the liver were always normal. However, 
because of incomplete observations (only 4 children had ulta-sound scans and of 
only 3 children alpha-fetoprotein was determined) we cannot be certain about this. 
The child that became HBsAg-positive at year 5, developed abnormal transaminases 
(ALAT 55 U/liter, ASAT 54 U/liter; normal less than 30 IU/liter) at year 8. 
Discussion 
In our neonatal hepatitis B vaccination program 9 out of 705 children 
became HBsAg-positive. Only one child suffered an symptomatic accute hapatitis 
B infection, which resulted in chronic hepatitis B. During follow-up 8 of the 9 
(89%) HBsAg-positive children remained HBsAg positive, without clinical 
abnormalities and 6 of these also without biochemical abnormalities. These data 
are consistent with other findings that the majority of children is asymptomatic at 
the time of onset of HBsAg-positivity (9) and that 80-90% of HBsAg-positive 
infants develops chronic hepatitis B, i.e. remains HBsAg-positive for more than 6 
months (5,9,10). This chronic hepatitis B is usually of a very mild nature, with 
normal serum amino-transferases (9,10). 
One child lost HBsAg in year 2. In our study the annual clearance rate of 
HBsAg was 3% (95% CI 0.4-22%); in the Taiwanese study describing the follow-
up of 420 hepatitis B-infected children, the corresponding percentage was 0.6% 
(5). Two children became HBeAg-negative within 2 and 3 years respectively. In 
our study the annual clearance rate of HBeAg was 7% (95% CI 3-19%); in the 
Taiwanese study the corresponding percentage was less than 2% (6). 
The HBsAg-positive children in the Taiwanese study were not vaccinated 
against hepatitis B, whereas the children in our study were. Data about the effect of 
hepatitis B vaccination on the course of hepatitis B after failed vaccination, have so 
far not been available. Examination of a greater number of HBsAg-positive 
children after failed vaccination would give us more insight into this. 
What are possible causes for the failure of neonatal hepatitis B vaccination? 
To answer this question we determined HBeAg and quantitative HBV-DNA of the 
mothers, and the HLA type of hepatitis B-infected children. 118 of the 705 (17%) 
of the HBsAg-positive mothers were HBeAg-positive as well; maternal HBeAg 
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was positive of all 8 children infected with hepatitis B during the first year of their 
lives. Maternal HBV-DNA of the infected children (median 314, range 152-597 
pg/ml) was significantly higher than in a control group of HBeAg-positive mothers 
of non-infected children (median 5, range 0-618 pg/ml) (11). We concluded that 
failure of immunisation was related to perinatal high maternal viral load (HBeAg, 
High HBV-DNA) and not to a genetically determined inability of the children to 
produce anti-HBs (11). 
The results from our study might serve as a basis for a policy regarding the 
follow-up of young children with chronic hepatitis B. Recently some articles have 
been published about the administration of alpha-interferon to children with 
chronic hepatitis B (12,13). A Spanish study describes a virological (loss of HBV-
DNA and HBeAg) and a biochemical (normalisation of ALAT) remission in over 
40% of 24 children between ages 1.5 and 5, with chronic active hepatitis B, at 9 
months after completion of a 6-months interferon therapy, against 17% remission 
in a control group were no alpha-interferon was administered (12). A Chinese 
study included asymptomatic children with normal serum transaminases; in this 
study no difference was found after 15 months in clearance percentage HBeAg of a 
control group (8%) and a group treated with interferon for 3 months (8%) (13). 
Therapy was tolerated well by children from both studies, side effects were mild 
and consisted of influenza symptoms, which disappeared after 2 weeks. Possible 
explanations for the different remission percentages can be found in the duration of 
the interferon therapy (Spanish study: 6 months, Chinese study: 3 months) and in 
the different selection of patients (Spanish study: children with chronic active 
hepatitis B (HBeAg-, HBV-DNA-positive) and raised serum amino-transferases, 
Chinese study: children with asymptomatic chronic hepatitis B with normal amino-
transferases. For adults with chronic hepatitis B the possibility of spontaneous 
HBeAg sera-conversion is closely linked to the serum amino-transferases, with the 
possibility of HBeAg sera-conversion twice as high with interferon therapy 
(14,15). As far as we know there is at present no standard therapy for chronic 
hepatitis B (HBeAg-positive) children. 
Given the possible serious complications of chronic hepatitis B (cirrhosis, 
hepato-cellular carcinoma) and given the availability of interferon, treatment of 
children with chronic hepatitis Band active viral replication (HBeAg-, HEY-DNA-
positive) must be considered. However, the clinical picture is usually so mild as to 
warrant the moderately effective interferon therapy only in the most obvious cases. 
We think it advisable to perform, in addition to anamnesis, physical and virological 
examinations, annual hepatic tests, and in the case of abnormalities a periodic 
ultra-sound scan of the liver. Only for patients having abnormal amino-transferases 
lasting longer than a yea:r, is there an increased risk of cirrhosis and is therapy 
medically indicated. In some cases the infectiousness of the patient may cause 
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great problems and in those cases therapy may be socially indicated. In order for a 
possible treatment to be started in the case of active viral replication and abnormal 
hepatic tests, check-ups should initially be carried out by a paediatrician. 
Children with chronic hepatitis B without active viral replication (HBeAg-
and HBV-DNA-negative) and with normal serum amino-transferases (ASAT, 
ALAT) do not qualify for anti-viral therapy and may be checked annualy by the 
family doctor to preclude reactivation. 
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Chapter 11 
Discussion: 
Ten year hepatitis B vaccination for prevention of 
neonatal hepatitis B: 
what has been achieved, what needs to be done? 
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Discussion 
Introduction 
After 10 year of neonatal hepatitis B vaccination, it has become clear that 
hepatitis B vaccine is safe and highly immunogenic; it also is very effective in 
preventing perinatally transmitted hepatitis B. New insights in the risk of maternal 
infant transmission appear important for the evaluation of vaccination programs 
and open the way for improving the efficacy of neonatal hepatitis B vaccination, 
especially in countries which rely on screening pregnant women for HBV and 
provide passive-active vaccination for infants at risk. In addition, universal 
neonatal hepatitis B vaccination has been advised by the World Health Organi-
zation for all countries by 1997 (1). Many countries have already integrated or are 
moving towards integrating hepatitis B vaccination into their standard immuni-
zation program for neonates (EPI: Expanded Programme on Immunization). 
Results of large immunization trials with long-term follow-up may help countries 
in planning (mass) hepatitis B immunization programs. 
Safety 
No clinically important side effects have occurred with any of the licensed 
vaccines (plasma- and recombinant- vaccine). Incidental cases of central-nervous-
system demyelination (2), uveitis (3), erythema nodosum (4) and systemic 
reactions (5) after hepatitis B vaccination have been reported, however a causal 
link between vaccination and these adverse effects has not been proved and has not 
been confirmed by others. With the introduction of recombinant-vaccine, the fears 
that other viruses (like HIV) might survive the manufacturing inactivation proce-
dures, necessary for preparing plasma-vaccine, have wained. In our study, of 705 
closely monitored infants, mild transient local symptoms were reported in 2.5% of 
infants vaccinated with 20 [kg Engerix-B and in 15% of infants vaccinated with 5 
and 10 [kg HB-Vax-DNA hepatitis B vaccine (6,7), in agreement with earlier results 
published (8,9). 
Immunogenicity 
Neonates generally respond well to both plasma- and recombinant vaccine. 
An anti-HBs level of more than 10 IU/L is considered to provide protection against 
clinical important forms of hepatitis B (10); anti-HBs response of more than 100 
IU/L implies long-lasting immunity (11). However the duration of immunity and 
the need for booster vaccinations have not yet been clearly established. 1-2% of 
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properly vaccinated infants of HBsAg-positive carrier mothers are not able to 
develop adequate amounts of anti-HBs for long-lasting immunity against hepatitis 
B. Both immunization and host factors affect the immune response to the hepatitis 
B vaccine. 
Immunization factors includes e.g. type, dose and schedule of vaccine. 
Enhancement of immunogenicity can be obtained by higher doses of vaccine 
(12,13), starting with vaccination if the infant is at an older age (14) and by using 
plasma- instead of recombinant- vaccine (15). In our study, anti-HBs levels 
measured after 12 months of follow-up were approximatively two times higher in 
infants receiving 3 doses of 10 f'g plasma-vaccine than in infants receiving only 
half of this dosage (16). This difference in anti-HBs response was no longer 
significant after 36 months of follow-up. In our study with recombinant-vaccine, 
there was no significant difference in immunogenicity between 10 and 5 ftg 
vaccine after 12 months of follow up (7). We confirmed the finding that plasma-
vaccine yields higher anti-HBs levels than recombinant-vaccine (16). Anti-HBs 
levels after immunization of infants at 3 months (concomitant with DTPP 
vaccination) were significantly higher than in infants who were vaccinated at 
birth (17,6), probably related to a more mature immune system of infants at 3 
months of age. The implications of this finding are not clear, it may become of 
importance if follow up results beyond 5-10 years become available. The 
observation that efficacy and immunogenicity are excellent when vaccination is 
started several months after birth, allows incorporation of hepatitis B vaccine in 
the routine infant immunization programme. Incorporation of hepatitis B vaccine 
into the existing Expanded Programme on Immunization (EPI) could reduce the 
number of doctor visits and could enhance compliance to both programmes. If 
protection against hepatitis B infection depends on persistence of antibody in a 
major way, then a strong argument could be made for adoption of schedules that 
maximize anti-HBs levels. Otherwise, adequate priming of the immune system, 
reflected by initial anti-HBs level of more than 100 IU/L after completion of 
vaccination is the goal of prevention (18). For the time being, until more long-
term follow up studies are present, it seems advisable to achieve an initial anti-
HBs response of more than 100 IU/L after vaccination for the prevention of late 
chronic hepatitis B. 
Infant immune responsiveness may depend on genetic causes (19). In our 
study, with only a small number of individuals, we found that 50% of (nonin-
fected) low responders (anti-HBs less than 10 IU/L) were positive for HLA-DR3. 
None of the infants that became HBsAg carriers was HLA-DR3 positive, sug-
gesting no genetic cause for the failure of hepatitis B immunization (20,21). Im-
paired immune responses to hepatitis B vaccine have been described in children 
undergoing hemodialysis (22), in children with malignancies (23) and in HIV 
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infected infants (24). In our study group, all (noninfected) low responders were in 
excellent health and diseases, that lower the activity of the immune system, were 
not observed. These low responders were not absolute low responders, since all of 
them developed protective anti-HBs levels after hepatitis B revaccination in their 
second year of life (25). We found no impaired immune response to hepatitis B 
vaccination in preterm infants in comparison with full term infants (26), in 
contrast with others (27). 
Efficacy 
The main goal of hepatitis B immunization is the prevention of the HBsAg 
carrier state and the sequalae, cirrhosis and hepatocellular carcinoma. Protective 
efficacy of more than 90% of passive-active immunization with plasma- and 
recombinant- hepatitis B vaccine has been described in programs for neonates (28-
31,14). In our study, the Protective Efficacy Rate (PER) at 12 month of age for 
infants of HBeAg positive carrier mothers was 92%, for infants of HBeAg negative 
mothers the PER was 100%. No effect on PER was found for timing of active 
immunization, number of doses of HBig and the type of vaccine (16), confirming 
previous observations (28,31). We found no need for a second dose of HB!g in 
combination with late-active immunization, but this finding has not been investiga-
ted by others. However, we found a major clinically relevant factor that influenced 
the PER. PER in the groups of infants with maternal HBV-DNA levels less than 
150 pg/ml was 100% and significantly higher than 68% in the group with maternal 
HBV-DNA level of more than 150 pg/ml. 
To verify the finding that the protective efficacy rate at 12 months of age is 
markedly influenced by maternal HBV-DNA levels, we reanalyzed the protective 
efficacy rate at 12 months of age according to quantified maternal HBV-DNA 
levels, in the Hong Kong neonatal hepatitis B vaccination programme (30,32,33) 
(table 1). In infants with maternal HBV-DNA levels of less than 5 pg/ml, no 
persistent HBsAg positivity at 12 months was detected, in agreement with our 
study. It was also confirmed that infants with maternal HBV-DNA levels of more 
than 150 pg/ml were at high risk for hepatitis B (25-50% of infants became 
persistent HBsAg positive) in spite of immunization. In infants with maternal 
HBV-DNA between 5-150 pg/ml, 15-28% of infants became HBsAg positive in the 
Hong Kong study. In the Dutch study no persistent HBsAg positivity was found. 
These results strongly support the concept that the level of maternal HBV-DNA is 
a major factor influencing the outcome of hepatitis B immunization. The absence 
of HBsAg carriers in the group with moderately high maternal HBV-DNA in our 
study, in comparison to 15-28% carrier rate in the Hong Kong study needs 
additional discussion. 
114 
Table 1. Failure of perinatal hepatitis B immunization in infants of HBeAg-carrier mothers, according to 
maternal HBV-DNA levels, in Hong-Kong and the Netherlands. 
Number of persistently HBsAg positive infants at 12 month(%) 
HBV-DNA Placebo vaccine only* HB!g/ HB!g! mult.HBig/ 
(pg!ml) vaccine* vaccine** vaccine*** 
group IV group III group II group 0 group I 
Hong Kong Hong Kong Hong Kong The Neth. Hong Kong 
n=78 < 5 0/9 (0%) 0/16 (0%) 0/13 (0%) 0/24 (0%) 0/16 (0%) 
n=\81 5-150 25/31 (81%) 11/40 (28%) 7/47 (15%) 0/24 (0%) 1!39 (3%) 
n=48 ~ 150 517 (71%) 4/8 (50%) 1/4 (25%) 7/24 (29%) 0/5 (0%) 
total 30/47 (64%) 15/64 (23%)t 8/64 (13%) 7/72 (10%)' 1!60 (2%)tt 
'HBlg single dose of 100 IU at birth (CLB, The Netherlands), 4 doses of 3 1-lg plasma-derived hepatitis B 
vaccine (CLB) 
" HB!g 1 or 2 doses at birth (and 3 month) of 200-300 lU (CLB), 4 doses of 10 1-lg plasma-derived 
hepatitis B vaccine (MSD) or 20 !J,g recombinant-DNA hepatitis B vaccine (SKB) 
*** HBig 7 monthly doses from birth onwards of 100 IU (CLB), 4 doses of 3 !J-g plasma-derived hepatitis 
B vaccine (CLB) 
t 1 infant became persistently HBsAg+ after 12 months of age 
tt 4 infants became persistently HBsAg+ after 12 months of age 
a maternal I-IBV-DNA in 1 persistent HBsAg+ infant not available 
We left group I out of consideration, because 4 of 5 infected infants became persistent HBsAg positive 
after 12 months of age, possible due to horizontal hepatitis B infection. 
Since the rate of intrauterine infection is estimated to be only 1-2% (30), the 
difference in HBV carrier rate is therefore likely due to differences in intervention 
(HB!g and vaccine) or to differences in maternal fetal transfusion during labour. 
Infants became persistent HBsAg positive after month 12 in the Hong Kong study, 
but not in our study. The dose of HB!g and vaccine might therefore be important 
for the prevention of late hepatitis B infection, in infants at risk for hepatitis B. Lee 
et a!. found that the number of infants with vertically transmitted HBV could 
significantly reduced by performing a Caesarean section, to reduce the amount of 
maternal fetal transfusion during labour (34). 
Recently, hepatitis B "escape mutants", lacking the "a" epitope on the viral 
envelope were found in vaccinated infants (35). The facts that we did not see a 
coexistence of HBsAg and anti-HBs positivity in 8 of 9 HBsAg positive infants 
and full neutralization of HBsAg by HB!g was obtained in all HBsAg positive 
children, make the presence of surface antigen variants in our study population 
highly unlikely. 
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Recommendations for hepatitis B immunization protocols 
EPI 
Hepatitis B vaccine can and should be incorporated into existing vacci-
nation programs for neonates (EP!: Expanded Programme on Immunization). A 
multivalent vaccine should be developed as rapidly as possible in order to reduce 
the number of injections and the number of doctor visits. 
Screening 
For countries with a hepatitis B screening program for pregnant women, in 
particular for countries which can afford high level individual care, assessment of 
the quantitative HBV-DNA level should be performed in all HBsAg-positive 
women that are also positive for HBeAg. Development of a cheap HBV-DNA 
quantitation assay is highly desirable. 
HBiglvaccine/additional measures 
For countries with hepatitis B screening program for pregnant women, one 
dose of HBig at birth in combination with delayed-active immunization, 
incorporated in EPI, appears the strategy of choice in view of efficacy, compliance 
and costs. In countries with high endemicity of hepatitis B, which can not afford 
screening, global vaccination without HB!g at birth might be the policy. During the 
last few years, the price of vaccines in developing countries has fallen to the point 
where widespread use of hepatitis B vaccine in EPI is feasible. There is need for 
confirmation of findings in large scale programmes. 
It is advised to offer at least 300 IU of HB!g and full dose of vaccine to 
neonates of HBsAg carrier mothers with maternal HBV-DNA level between 5 and 
150 pg/ml. 
Additional measures are required for infants at highly risk with maternal 
HBV-DNA level of more than 150 pg/ml; to enhance the capture of HBV during 
the first days of life, the use of a higher dose of HB!g at birth should be studied. To 
reduce maternal fetal transfusion during labour, the role of Caesarean section 
should be reevaluated in a schedule using current doses of HB!g and vaccine. 
Efficacy of HBig dosage and vaccine schedules should be assessed in 
neonates with defined maternal HBV-DNA levels. Vaccine types and schedules 
should be used, providing adequate immune response beyond the first year. Such 
vaccine programmes are in general defined by initial anti-HBs response of more 
than 100 IU/L in more than 95% of vaccinees. 
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Preterm infants 
Infants with a gestational age of less than 37 weeks should be vaccinated, at 
similar age as term infants, without correction for their shortened gestational age. 
Infants with low /no response to hepatitis B vaccine 
Infants with an inadequate anti-HBs response after primary vaccination and 
who remained HBsAg negative, should receive additional hepatitis B vaccinations 
in their second year of life. 
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Summary 
Chapter 2 
Chapter 2 describes the protective efficacy of passive-active immunization 
in 80 high-risk infants after a follow-up of 5 years. Infants received either early 
active immunization starting at birth in combination with HB!g at birth (group A) 
or late active immunization starting at 3 months of age in combination with HB!g 
at 0 and 3 months of age (group B). During the study period 3 of 35 infants in 
group A and 3 of 37 infants in group B became HBsAg carriers, corresponding to 
an incidence of infection of 9% and 8%, respectively. Subclinical infections were 
diagnosed in 4 infants in each group. Late active-immunization starting at 3 months 
of age appears to provide similar protective efficacy as active immunization 
starting at birth when combined with hepatitis B immune globulin at 0 and 3 
months of age. Late active hepatitis B immunization starting at 3 months of age 
could be given at the same time as DTPP immunization. Incorporation of hepatitis 
B immunization in the existing DTPP program may increase compliance and 
decrease costs. 
Chapter3 
Chapter 3 describes the immunogenicity of a full dose of recombinant 
DNA yeast-derived hepatitis B vaccine (Engerix-B) in healthy neonates of HBsAg 
negative mothers. Three candidate vaccinations schemes were compared. 
Neonates received 4 doses of hepatitis B vaccine, starting either at month 3 or at 
birth. Another group of neonates received hepatitis B vaccine according to a 
three-dose scheme starting at birth. The vaccine was highly immunogenic irre-
spective of vaccination scheme; all infants developed anti-HBs levels of more 
than 10 IU/L, 97% more than 100 IU/L. The immunogenicity of hepatitis B 
vaccine administered in the four-dose scheme starting at birth was significantly 
higher than in the three-dose scheme starting at birth. Hepatitis B vaccination 
according to the four-dose scheme started at month 3 produced significantly 
higher antibody levels in comparison to the four-dose scheme started directly after 
birth. 
Chapter 4 
Chapter 4 describes the immunogenicity of one half and a full dosage of 
recombinant DNA yeast-derived hepatitis B vaccine (HB-Vax-DNA) in healthy 
neonates of HBsAg negative mothers. Two candidate dosages of the vaccine were 
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compared. Neonates received four doses of one half (5 ~-tg) or a full (10 1-tg) dosage 
of vaccine, concomitant with DTP-Polio immunization. The vaccine was highly 
immunogenic not related to dosages of vaccine; all infants developed anti-HBs 
levels of more than 10 IU/L and 99% more than 100 lU/L. 
ChapterS 
Chapter 5 describes the efficacy and long-term immunogenicity of the ten-
year neonatal hepatitis B vaccination program 1982-1992. 705 infants born to 
HBsAg positive mothers entered the Dutch neonatal hepatitis B vaccination and 
received passive-active hepatitis B immunization, according to 6 schedules, 
varying in time of onset vaccination, dose of HBlg and type and dose of vaccine. 
118 (17%) of the mothers were also HBeAg positive. During follow up, 9 infants 
became HBsAg carriers; all born to HBeAg positive mothers within the first year 
and another child, born to HBeAg negative mother at the age of 5 years. Protective 
Efficacy Rate (PER) of passive-active hepatitis B immunization at 12 months 
follow up in the total group was 92% with no significant difference in groups 
starting at birth or at 3 months; groups receiving one or two doses of HB!g; groups 
receiving plasma- derived or recombinant- vaccine. PER at month 12 in the group 
with maternal HBV-DNA levels < 150 pg/ml was 100% and significantly higher 
than 68% for the group with HBV-DNA levels" 150 pg/ml. After 5 years of follow 
up, the group with active immunization starting at 3 months had significantly less 
infants with anti-HBs levels less than 10 IU/L (2%) than the corresponding group 
starting at birth (15%). The GMT anti-HBs (anti-HBs" 10 IU/L) was significantly 
higher in the group, starting at 3 months of age with plasma vaccine than in the 
corresponding group starting at birth and also higher than in the corresponding 
group, using recombinant vaccine. This program showed that hepatitis B vaccine is 
highly effective and immunogenic in the prevention of neonatal hepatitis B. 
Evaluation of vaccination programs according maternal HBV-DNA levels is 
important for improving results of intervention for those infants at highest risk of 
vertically transmitted hepatitis B. 
Chapter6 
Chapter 6 The immune response after passive-active hepatitis B immuniza-
tion of 44 preterm neonates (gestational age of less than 37 weeks) was compared 
with the immune response of 829 full term infants. No significant differences 
between preterm infants and full term infants in the percentages with anti-HBs 
titers more than 10 IU/L and more than 100 IU/L were found. The percentages of 
children with anti-HBs titers more than 10 IU/L and more than 100 IU/L who 
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started vaccination at birth were lower than the corresponding percentages of 
infants who started at month 3, but they were similar for preterm and full term 
infants. There was no significant difference in immune response after completion 
of the primary vaccinations between preterm infants weighing less and those 
weighing more than 2000 grams. The anti-HBs titers at month 3 of 2 preterm 
infants receiving exchange transfusions, were significantly lower than for infants 
without exhange transfusions. Replacement of plasma shortly after passive 
immunization could theoretically lead to inadequate protection against hepatitis B 
infection. Administration of additional doses of HB!g, after exhange transfusion, 
would probably prevent the risk of hepatitis B infection. Although there was only 
one child with a gestational age of less than 28 weeks in our study, we support the 
recommendation of the American Academy of Pediatrics to administer hepatitis B 
vaccine as well as diphtheria, tetanus and pertussis vaccine to preterm infants at the 
appropriate chronological age. 
Chapter 7 
Chapter 7 describes the results of additional hepatitis B vaccination of 
infants, who had a non-detectable or a weak response after primovaccination (anti-
HBs ,; 10 IU/L) and no signs of hepatitis B infection. Nine infants received 3-4 
additional doses of plasma-derived (10 [.lg) or recombinant-DNA (20 [.lg) vaccine 
in their second year of life. After revaccination all infants showed an anti-HBs 
response above 10 IU/L; 7 children developed more than 50 IU/L and 4 of them 
more than 100 IU/L. Since many of these children remain at risk for hepatitis B 
infection due to family contacts, it seems important to determine anti-HBs levels 
after vaccination and to offer additional doses of hepatitis B vaccine to HBsAg 
negative children with an anti-HBs level less than 10 IU/L. 
Chapter 8 
Chapter 8 showed the HLA phenotypes of the 8 noninfected low responders 
(HBsAg negative, anti-HBs less than 10 IU/L) and the 8 infected nonresponders 
(HBsAg positive, anti-HBs negative) to hepatitis B vaccine. HLA-DR3 was present 
in 4 of the 8 noninfected low responders and in none of the 8 infected 
nonresponders. Two noninfected low responders were probably homozygous for 
HLA-DR3. This study suggested that the HLA-DR3 haplotype plays a role in the 
low responsiveness to hepatitis B vaccination in noninfected neonates but not in 
HBsAg positive neonates, in which vaccination failed. 
124 
Chapter9 
Chapter 9 describes the results of studies to hepatitis B immunization 
failure. In order to determine whether failure of the hepatitis B vaccination was due 
to perinatal maternal high-level viraemia or genetically determined infant non-
responsiveness to the vaccine, we measured HBeAg and HBV-DNA levels in 
maternal serum and determined the HLA type of the 8 infected nonresponders 
(group 1). Controls included 14 infants with a normal anti-HBs response 1 year 
after vaccination, noninfected responders (group 2), and the 8 noninfected low 
responders (group 3). All infants in group 1 and 2 were born of HBeAg carrier 
mothers, those in group 3 of HBeAg-negative mothers. HBV-DNA levels in 
maternal serum in group 1 were significantly higher than in group 2 and 3. HLA 
B8 and DR3 were not found in group 1 (chapter 8). It is believed that intra-uterine 
HBV infection occurs in 1-2% of infants of HBeAg positive HBV carrier mothers. 
For a similar incidence in our study, intra-uterine infections can be expected in 2 
infants of 118 HBeAg carrier mothers. The remaining causes of failure of hepatitis 
B vaccination appears to be related not to genetic nonresponsiveness of infants but 
rather to perinatal maternal high-level viraemia. HBV-DNA assay of HBeAg-
positive mothers may identify those infants in need of additional action to lower 
the risk of vertically transmitted HBV infection. 
Chapter 10 
Chapter 10 describes virological. clinical and biochemical characteristics of 
HBV in infants, who became hepatitis B infected, in spite of passive-active 
hepatitis B immunization. Nine of 705 vaccinated infants became positive for 
HBsAg. Median follow up was 5 years (range 3-8 years). Eight of the 9 infants 
were also positive for HBeAg. At the end of the follow up, 1 child lost HBsAg and . 
2 children lost HBeAg. Only 1 child experienced a symptomatic hepatitis B 
infection with raised transaminase levels. The other 8 infants with chronic hepatitis 
B were not symptomatic and were in excellent health. Transaminase levels were 
ever normal in 7 infants. The conclusion was that most of the infants, who became 
HBsAg positive, in spite of passive-active hepatitis B immunization, developed a 
chronic hepatitis B infection, without clinical and biochemical dysfunctions. On 
the basis of these findings and recent literature, concerning possible therapy, 
guidelines were given for the follow up of children with chronic hepatitis B. 
Antiviral therapy should be considered for chronically HBV infected children with 
active viral replication (HBeAg and HBV-DNA positive) and raised transaminase 
levels for 1 year. 
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Samenvatting 
Hoofdstuk2 
Hoofdstuk 2 beschrijft de effectiviteit van passieve-actieve immunisatie 
van 80 pasgeborenen met een groot risico op hepatitis B na een observatie-
periode van 5 jaar. Na randomisatie, ontvingen kinderen vroege actieve immu-
nisatie, de eerste dosis vaccin in combinatie met HB!g, direct na de geboorte 
(groep A) of late actieve immunisatie, de eerste dosis vaccin op 3 maanden in 
combinatie met HB!g direct na de geboorte en op de leeftijd van 3 maanden 
(groep B). Drie van 35 kinderen in groep A en 3 van 37 kinderen in groep B 
werden HBsAg positief. Subklinische infecties werden in 4 kinderen van elke 
groep gediagnostiseerd. De effectiviteit van late actieve immunisatie, gecombi-
neerd met HB!g op maand 0 en 3, was gelijk aan de effectiviteit van vroege 
actieve immunisatie. Late actieve hepatitis B immunisatie, waarbij de eerste 
dosis op de leeftijd van 3 maanden wordt gegeven, kan tegelijkertijd met de 
DKTP vaccinatie plaatsvinden. lncorporatie van hepatitis B vaccin in het 
bestaande DKTP programma kan de kosten verminderen en de bereidheid tot 
deelname aan het programma vergroten. 
Hoofdstuk3 
Hoofdstuk 3 beschrijft de immunogeniciteit van een vo lwassen dosis 
recombinant DNA hepatitis B vaccin (Engerix-B) in gezonde pasgeborenen van 
HBsAg negatieve moeders. Drie vaccinatie schema's werden vergeleken. Bij de 
eerste groep kinderen werd de vaccinatie direct na de geboorte gestart en 3 maal 
herhaald. Bij een tweede groep kinderen werd eveneens direct na de geboorte 
gestart en de vaccinatie slechts 2 maal herhaald. Bij een derde groep kinderen werd 
op de leeftijd van 3 maanden de eerste vaccinatie gegeven en werd deze 3 maal 
herhaald. De immunogeniciteit van het vaccin was groot, onafhankelijk van het 
gebruikte schema; alle kinderen produceerden een anti-HBs titer van meer dan 10 
IE/L, 97% meer dan 100 !E/L. De immunogeniciteit van hepatitis B vaccin in het 
schema met 4 doses vanaf de geboorte was significant grater dan van het schema 
met 3 doses vanaf de geboorte. Hepatitis B vaccinatie volgens het 4 doses schema, 
waarbij de eerste dosis op de leeftijd van 3 maanden wordt gegeven, gaf hogere 
anti-HBs titers dan het 4 doses schema waarbij de eerste dosis direct na de 
geboorte werd gegeven. 
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Hoofdstuk4 
Hoofdstuk 4 beschrijft de immunogeniciteit van een halve en een hele dosis 
recombinant DNA hepatitis B vaccin (HB-Vax-DNA) bij gezonde kinderen van 
HBsAg negatieve moeders. Twee mogelijke schema's werden vergeleken. 
Kinderen ontvingen 4 maal een halve (5 f.lg) of een hele (10 f.lg) dosis vaccin, 
tegelijkertijd met de DKTP vaccinatie. De immunogeniciteit van het vaccin was 
groat en niet gerelateerd aan de dosis; alle kinderen ontwikkelden anti-HBs titers 
van meer dan 10 IE/L en 99% meer dan 100 IE/L. 
HoofdstukS 
Hoofdstuk 5 beschrijft de effectiviteit en lange-termijn immunogeniciteit 
van bet 10-jaar neonatale hepatitis B vaccinatie programa 1982-1992.705 kinderen 
van HBsAg positieve moeders namen dee! aan het programma en ontvingen 
passieve-actieve hepatitis B immunisatie, varierend in tijdstip van starten 
vaccinatie, dosis HB!g en type en do sis vaccin. 118 (17%) van de moeders waren 
oak HBeAg positief. Gedurende de observatie-periode werden 9 kinderen HBsAg 
positief; 8 kinderen, allemaal van HBeAg positieve moeders, in bet eerste levens-
jaar en 1 kind van een HBeAg negatieve moeder, op de leeftijd van 5 jaar. De 
effectiviteit van passieve-actieve hepatitis B immunisatie na een observatie-duur 
van 12 maanden bedroeg 92% in de totale groep; geen significante verschillen 
werden gevonden in de groepen waarbij de eerste dosis werd gegeven direct na de 
geboorte of op de leeftijd van 3 maanden; in de groepen die 1 of 2 doses HB!g 
ontvingen of in de groepen die plasma of recombinant vaccin ontvingen. De 
effectiviteit op maand 12 in de groep met maternale HBV-DNA < 150 pg/ml was 
100% en significant grater dan de 68% in de groep met HBV-DNA " 150 pg/ml. 
Na een observatie-periode van 5 jaar had de groep die de eerste dosis vaccin op de 
leeftijd van 3 maanden ontving significant minder kinderen met anti-HBs titers 
minder dan 10 IE/L (2%) dan de overeenkomstige groep die de eerste dosis vaccin 
direct na de geboorte ontving (15%). GMT anti-HBs (anti-HBs " 10 IE/L) was 
siginificant hager in de groep met de eerste dosis plasma vaccin op de leeftijd van 
3 maanden dan in de overeenkomstige groep met de eerste dosis vaccin direct na 
de geboorte en oak hager dan de overeenkomstige groep met recombinant vaccin. 
In dit programma was de effectiviteit van hepatitis B vaccin groat in de preventie 
van neonatale hepatitis B. Vaccinatie programma's evalueren aan de hand van 
maternale HBV-DNA lijkt zinvol voor het verbeteren van resultaten van interventie 
bij kinderen met het hoogste risico op verticaal verworven hepatitis B. 
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Hoofdstuk6 
Hoofdstuk 6 De immuunrespons na passieve-actieve hepatitis B immunisatie 
van 44 praematuren (zwangerschapsduur minder dan 37 weken) werd vergeleken 
met de immuunrespons van 829 a terme geboren kinderen. Er werden geen signi-
ficante verschillen gevonden tussen praematuren en a terme geboren kinderen in de 
percentages kinderen met anti-HBs titers meer dan 10 IE/L en meer dan 100 IE/L. 
Er was geen significant verschil in immuunrespons tussen praematuren met een 
gewicht van minder dan 2000 gram of van meer dan 2000 gram. De anti-HBs titers 
op maand 3 van 2 praematuren die wisseltransfusies toegediend kregen, waren 
significant lager dan die van kinderen zonder wisseltransfusies. Het wegnemen van 
plasma kart na toediening van HBlg zou theoretisch kunnen leiden tot onvoldoende 
protectie tegen hepatitis B. Het toedienen van extra HBlg aan kinderen die wissel-
transfusies krijgen zou het risico op hepatitis B kunnen verminderen. Alhoewel er 
slechts een kind een zwangerschapsduur van minder dan 28 weken had, ondersteunt 
deze studie vooralsnog het advies van de Gezondheidsraad om hepatitis B 
vaccinatie van praematuren te starten op de kalenderleeftijd, zonder te corrigeren 
voor de vroeggeboorte. 
Hoofdstuk 7 
Hoofdstuk 7 beschrijft de resultaten van additionele hepatitis B vaccinatie 
van kinderen, met een niet-detecteerbare of zwakke immuunrespons na de eerste 
vaccinaties (anti-HBs ,; 10 IE/L) en die geen hepatitis B hadden. Negen kinderen 
ontvingen 3-4 additionele doses plasma (10 fig) of recombinant (20 ftg) vaccin in 
hun tweede levensjaar. Aile kinderen hadden anti-HBs titers van meer dan 10 IE/L 
na revaccinatie, 7 kinderen meer dan 50 IE/L en 4 meer dan 100 IE/L. Omdat vee! 
van deze kinderen een verhoogd risico op hepatitis B houden door familie-
contacten, lijkt het belangrijk om de anti-HBs titers na vaccinatie te bepalen en om 
additionele doses hepatitis B vaccin aan te bieden aan HBsAg negatieve kinderen 
met een anti-HBs titer kleiner dan 10 !E/L. 
Hoofdstuk8 
Hoofdstuk 8 laat de HLA phenotypes van de 8 niet-gelnfecteerde !age 
responders (HBsAg negatief, anti-HBs minder dan 10 lE/L) en van de 8 gelnfec-
teerde niet-responders (HBsAg positief, anti-HBs negatief) op vaccinatie zien. 
HLA-DR3 was in 4 van de 8 niet-gelnfecteerde !age responders en in geen van de 8 
gelnfecteerde niet-responders aanwezig. Twee niet-gelnfecteerde !age responders 
waren waarschijnlijk homozygoot voor HLA-DR3. Deze studie suggereert dat het 
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HLA-DR3 haplotype een rol speelt in de !age immuunrespons op hepatitis B 
vaccinatie in niet-gelnfecteerde neonaten maar niet in HBsAg positieve kinderen, 
waarbij vaccinatie faalde. 
Hoofdstuk9 
Hoofdstuk 9 beschrijft de resultaten van onderzoek naar oorzaken van falen 
hepatitis B vaccinatie. Om te bepalen of perinatale maternale hoge virale druk of 
genetisch bepaald onvermogen van het kind om op vaccinatie te reageren de 
oorzaak was van falen van hepatitis B vaccinatie, werden het HBeAg en HBV-
DNA in maternale sera en het HLA-type van de 8 gelnfecteerde niet-responders 
bepaald (groep 1). Als controles fungeerden 14 kinderen met een normale anti-HBs 
respons 1 jaar na vaccinatie, niet-ge'infecteerde responders (groep 2) en de 8 niet-
gelnfecteerde !age responders (groep 3). Alle moeders van de kinderen van groep 1 
en 2 waren HBeAg positief, van de kinderen van groep 3, HBeAg negatief. HBV-
DNA in maternaal serum van groep 1 was significant hoger dan van groep 2 en 3. 
HLA B8 en DR3 werden niet in groep 1 gevonden (hoofdstuk 8). Intra-uterine 
infecties zouden in 1-2% van de kinderen van HBeAg positieve moeders met 
chronische hepatitis B voorkomen. Bij een overeenkomstige incidentie in deze 
studie, werden ten hoogste 2 intra-uterine gelnfecteerde kinderen, van 118 HBeAg 
positieve moeders, verwacht. De overige oorzaken van falen van hepatitis B 
vaccinatie lijkt niet gerelateerd aan genetische bepaald onvermogen van het kind 
om op vaccinatie te reageren maar aan perinatale maternale hoge virale druk. Het 
bepalen van HBV-DNA bij HBeAg positieve moeders kan die kinderen identi-
ficeren met een hoog risico op verticaal verkregen hepatitis B. 
Hoofdstuk 10 
Hoofdstuk 10 beschrijft het virologische, klinische en biochemisch beloop 
van de hepatitis B infectie in kinderen, die ondanks passieve-actieve hepatitis B 
immunisatie loch HBsAg positief werden. Negen van de 705 gevaccineerde 
kinderen werden HBsAg positief. De mediane observatie-periode bedroeg 5 jaar 
(spreiding 3-8 jaar). Acht van de 9 kinderen waren !evens HBeAg positief. Aan het 
eind van de observatie-periode had 1 kind HBsAg en 2 HBeAg verloren. Slechts 1 
kind maakte een symptomatische hepatitis B infectie met verhoogde serum-
transaminasen door. De overige 8 kinderen met chronische hepatitis B waren 
zonder symptomen en verkeerden in goede algemene gezondheid. De serumtrans-
aminasen van 7 kinderen waren immer normaal. De conclusie was dat het 
merendeel van de kinderen die HBsAg positief werden, ondanks passieve-actieve 
hepatitis B immunisatie, een chronische hepatitis B ontwikkelden, zonder klinische 
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en biochemische afwijkingen. Op grand van deze bevindingen en recente literatuur, 
betreffende mogelijke therapie, worden richtlijnen voor de begeleiding van 
kinderen met chronische hepatitis B gegeven. Antivirale therapie voor kinderen 
met chronische hepatitis B en actieve virale replicatie (HBeAg en HBV-DNA 
positief) met verhoogde serumaminotransferasen gedurende 1 jaar, moet over-
wogen worden. 
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